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Abstract 
Chronic kidney disease (CKD) is a common disorder that currently serves as a major global public 
health issue due to raised risk of cardiovascular disease (CVD), kidney failure, and other 
complications. With the ever-growing increase of ageing populations and rising global frequency 
of diabetes and other chronic non-transmissible diseases, present clinical data suggests a 
corresponding worldwide increase in prevalence of chronic kidney disease and end-stage renal 
failure (ESRF). 
The overall aims of this thesis was to study the prevalence of known traditional and novel CKD 
related risk factors in a non-clinical population, examine the applicability of several predictive 
equations in the estimation of GFR for the stratification of CKD, Investigate the relationships 
between key risk factors amongst different subgroups of the total study population, and Provide 
evidence in the need for further healthcare screening strategies to help identify early onset CKD. 
This project carried out quantitative and qualitative assays to investigate the Incidence of 
chronic kidney disease risk factors in a non-clinical, mixed-age university population and 
establish the risk of development of CVD, CKD and type 2 diabetes. Baseline information was 
reported on a questionnaire and blood serum samples were analysed for biochemical 
components including blood glucose, cholesterol, triglycerides, creatinine, fructosamine and 
high sensitive C-reactive protein. Renal status was measured using the Kidney Disease: 
Improving Global Outcomes (KDIGO) classification. 186 individuals (64% females) were recruited 
and separated into two age groups (under and over 30 years). 
Overall, 39% of participants showed a BMI above 25 with 13% indicating levels above 30. Kidney 
function data revealed 21% of participants with an estimated glomerular filtration rate below 
90ml/min/1.73m2. Preliminary data suggests a significant difference in diastolic blood pressure, 
body fat percentage and renal function between the two age groups. Regarding biomarkers of 
CKD, the dominant finding was a strong relationship between the markers of glycaemic control 
and a reduced eGFR. Likewise, this relationship was also visible in the lipid markers of the study 
population.  
In summary, the findings from this study in combination with previous reports suggest that 
traditional biochemical risk markers such as those for diabetes and obesity may share an 
increased relationship with a reduced kidney function. While we did not see a direct correlation 
between the non-traditional marker, hsCRP, it was possible that this was a consequence of 
insufficient population numbers. 
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Investigation of renal equations provided evidence of a greater accuracy in the measurement of 
estimated kidney function using the newer equation system, CKD-EPI, in comparison to clinically 
regarded formulas such as Cockcroft-Gault and MDRD. 
When evaluated on an additive scale, the modification of these variables by the presence of 
other risk factors has important clinical and public health implications with respect to CKD case 
findings and mass screening strategies. 
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1.1 Background  
Chronic kidney disease (CKD) is a common disorder that currently serves as a major global public 
health issue due to raised risk of cardiovascular disease (CVD), kidney failure, and other 
complications (El Nahas, 2005 and Oh et al., 2010). With the ever-growing increase of ageing 
populations and rising global frequency of diabetes and other chronic non-transmissible 
diseases, present clinical data suggests a corresponding worldwide increase in prevalence of 
chronic kidney disease and end-stage kidney failure (James et al., 2010). Due to the progressive 
nature of CKD and subsequent end-stage renal disease (ESRD), considerable pressure is being 
placed around the quality and availability of global healthcare resources (El Nahas and Bello, 
2010). Despite the vast number of risk profilers and related therapies available to clinical 
patients, the suboptimal status of cardiovascular (CV) and renal protection still remains high in 
healthcare settings. Many reasons for this are indicated by the progression to ESRD or CV events 
in patients who receive optimal treatment, thus suggesting the need for newer, better 
predictors or, more importantly, new therapy targets (Zeeuw et al., 2005).  
1.2 Functions of the Kidney 
 The kidney is a complex organ which is key to many of the functions that take part in the body. 
It removes a number of toxins, excess salts and waste products through filtering of the blood as 
well as controlling the balance of water and pH levels and regulating blood pressure (Levey et 
al., 2003). Each kidney consists of around one million nephrons, each containing glomeruli, 
capillaries, arterioles, and tubules. Regulation of blood pressure is carried out through a number 
of ways, this includes the renin-angiotensin aldosterone system (RAAS) which acts to maintain 
blood pressure and fluid homeostasis through the constriction of vessels and retention of water 
and minerals (Coresh et al., 2005). The kidneys also act as an endocrine organ by producing 
erythropoietin, which controls the production of red blood cells. Furthermore, the kidneys also 
play a role in the calcium-phosphorus metabolism process whereby calcium is reabsorbed in the 
tubular system. In cases such as CKD, calcium levels become depleted, thus the kidneys activate 
a compensatory increase in parathyroid hormone (PTH), resulting in the stimulation of vitamin 
D to facilitate the absorption of calcium from the small intestine and increase calcium and 
phosphate efflux from bone (Sahay, 2012).  
1.3 Definition, classification and staging 
Unlike most diseased group patients, those with CKD do not share a common underlying 
diagnosis and as a result, the pathophysiology and natural history may differ significantly 
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between same-group individuals. However, it was acknowledged by the authors of the 
guidelines that these patients did have one thing in common; decreased kidney function due to 
a chronic disease process. They also established the variance in markers of impaired kidney 
function in differing diagnoses (Ikizler, 2009). However, despite these observations, once kidney 
disease is established the features that define CKD apply across disease states and comprise 
evidence of damaged renal parenchyma as demonstrated by active urinary sediment and/or 
structural abnormality (must be present for stages 1 and 2) and/or evidence of decreased kidney 
function as demonstrated by a reduced glomerular filtration rate (GFR) and chronicity to 
distinguish it from acute kidney injury (AKI) (Parr and Siew, 2014).   
Worldwide, the growing number of patients with ESRD is continuing to act as a burden amongst 
populations despite the recent advances in our understanding of the uraemic state and 
improvements in the science and technology of renal replacement therapy (Ikizler, 2009). Over 
1 million people are estimated to suffer from ESRD in the world today (NxStage Medical, 2012). 
These findings have led the scientific community, now over a decade ago, to identify CKD as an 
‘important public health problem’ which emphasises the need for timely diagnosis and 
treatment for prevention of ESRD (Ikizler, 2009). The definition and classification of CKD 
guidelines were first introduced by the National Kidney Foundation (NKF) Kidney Disease 
Outcomes Quality Initiative (KDOQI) in 2002 (National Kidney Foundation, 2002), and later 
adopted internationally by the Kidney Disease: Improving Global Outcomes (KDIGO) initiative to 
guide identification of cases and facilitate management (Levey et al., 2005). Subsequently, these 
CKD guidelines have helped shift the concept of kidney disease from that of an uncommon life-
threatening condition that requires care by clinical nephrologists to that of a common condition 
with a range of severity and thus warranting attention by general internists and demanding the 
application of tactics for early diagnostic measures, preventative strategies and managerial 
procedures (Levey et al., 2009). 
In general, CKD is defined as “structural or functional abnormalities of the kidney that persist for 
at least 3 months and are manifested by either kidney damage (most frequently detected as 
persistent albuminuria; >30 mg albumin/g creatinine) or a sustained reduction in glomerular 
filtration rate (GFR) (<60 mL/min per 1.73m2)” (Levey et al., 2009). The recommended screening 
methods for detection of CKD involves the use of ‘untimed urine checks’ for the presence of 
proteinuria, measuring the albumin:creatinine ratio (>30 mg/g as designated cut-off point), 
ultrasonographic images (e.g., cysts in adult polycystic kidney disease), and/or total 
protein:creatinine (>200mg/g) (NICE, 2014). Assessment of kidney function is often carried out 
through either the direct measurement of GFR (mGFR), using urinary or plasma clearance of 
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exogenous filtration markers such as inulin, or most frequently through the estimation of GFR 
(eGFR) via serum creatinine levels (Stevens and Levey, 2009).  
To avoid the misclassification of individuals based on serum creatinine alone, a number of well-
known eGFR equations have been developed which include additional features such as age, sex, 
ethnic origin, and body size (Slee, 2012). The Cockcroft-Gault equation, which was introduced in 
1976, was subsequently used by many clinical services in routine practice for the determination 
of eGFR (Cockcroft and Gault, 1976). Although the formula is still currently in use for purposes 
such as dose adjustments for renal clearance-related drugs, it presents as a complex formula 
which requires anthropometric measurements that may not be routinely available, and in some 
cases, has been known to overestimate GFR (Levey et al., 1999).  
The modification of diet in renal disease (MDRD) study equation is one of the most well-known 
and clinically embedded formulas currently in use. Developed by Levey et al in 1999, the MDRD 
equation provides an estimation of GFR using patients’ serum and other readily available data. 
However, likewise to the Cockcroft-Gault formula, much criticism has been called out by 
researchers on the accuracy of the MDRD equation, with many arguing that this formula has the 
tendency to underestimate in individuals who present a GFR above 90 ml/min/1.73m2 (Murata 
et al., 2011). The potential risk and severity of CKD using the five-stage scheme is based 
predominantly on GFR (table 1.1), however risk of complication at a given rate can be altered 
considerably by the amount of proteinuria produced by the patient. 
Since the concentration of creatinine in serum alone is insensitive to early disease, identification 
and staging of chronic kidney disease on the basis of estimated glomerular filtration rate was an 
important advance that was able to facilitate both research and clinical care. Nonetheless, 
controversy continues to surround the existing classification system, specifically with regard to 
its propensity to overestimate prevalence; its failure to fully incorporate prognostic information 
from proteinuria; and the potential for misclassification of some people as having CKD in the 
absence of clinically relevant kidney disease (James et al., 2010). 
  
Table 1.1 Classification of chronic kidney disease stages 1-5 
 
Stage Description GFR                 
(ml/min/1.73 m2) 
Clinical Presentations 
- At increased risk > 60 (without markers 
of damage) 
CKD risk factors 
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CKD is defined as either kidney damage or GFR <60 mL/min/1.73 m2 for >3 months. Kidney damage is defined as 
pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.  
(Adapted from: KDIGO CKD Work Group, 2012. Clinical Practice Guideline for the Evaluation and Management of 
Chronic Kidney Disease. Table 1.2.3). 
1.4 Epidemiology 
Evidently, it cannot be ignored that CKD prevalence across the world is growing at a substantial 
rate. With an estimated global disease prevalence of between 10% to 16% in adults and an 
annual growth rate of 8% in ESRD incidence, figures indicate a vastly growing issue surrounding 
the renal health status of many populations (Chan, 2012). As CKD is often asymptomatic, studies 
to determine its prevalence must rely on community-based screening. As Table 1.2 shows, there 
is considerable variation in prevalence depending on the methods used and the populations 
studied (Evans and Taal, 2011). In the UK, the HSE 2010 study provided data from more than 
6,000 participants in which 49% of men and 52% of women were reported to have abnormal 
eGFR levels (below 90ml/min/1.73m2). Nonetheless, a much lower proportion of individuals 
were described as having an eGFR below 60ml/min/1.73m2 (6% of men and 7% of women). Most 
apparent from this is the gradual decrease in eGFR with increasing age in both genders, from 1% 
of men and fewer than 1% of women aged 16-24 to 28% of men and 35% of women aged 75 
and over, as illustrated in figure 1.1 (Roth et al., 2011).  
1 Kidney damage with normal 
or increased GFR 
>90 Markers of damage 
(nephrotic syndrome, 
nephritic syndrome, 
tubular syndromes, 
urinary tract 
symptoms, 
hypertension due to 
kidney disease) 
2 Kidney damage with mildly 
diminished GFR 
60-89 Mild complications 
3a Mildly to moderately 
decreased GFR 
45-59 
Moderate 
complications 3b Moderately to severely 
decreased GFR 
30-44 
4 Severely decreased GFR, with 
or without other evidence of 
kidney damage 
15-29 Severe complications 
5 Kidney failure <15 (or dialysis) Uraemia, 
Cardiovascular disease 
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Table 1.2 CKD prevalence in a range of populations 
(Adapted from: Evans and Taal, 2011. Epidemiology and causes of chronic kidney disease. Table 1). 
 
Although we have little information on the total burden of CKD in the UK, data from other 
studies such as the National Health and Nutrition Examination Surveys (NHANES) in the USA not 
only gives likely overall population prevalence, but also suggests that the prevalence is 
increasing (Coresh et al., 2007). Comparison between the prevalence of CKD in NHANES 1988-
1994 with NHANES 1999-2004 showed a significant increase in population prevalence from 
10.03% to 13.07% (National Collaborating Centre for Chronic Conditions, 2008). Many 
researchers suggest that this rising prevalence in CKD has been brought about by the current 
escalation in CKD risk factors including obesity, hypertension and most notably the rise in ageing 
populations across America and much of the world; the incidence of ESRD is much higher in 
elderly people than in the general population (more than 1200 per million in over 65’s in 
America) (El Nahas and Bello, 2005). Despite this remarkable rise in related risk factors, one 
disease continues to make itself known amongst renal sufferers across the globe, that is, type 2 
diabetes mellitus (T2DM). Recent estimates suggest that T2DM accounts for 382 million 
sufferers worldwide, and as a result, diabetic nephropathy is now one of the leading causes of 
ESRD, accounting for 30-40% of all kidney-related diseases (El Nahas and Bello, 2005). This 
noticeable rise in incidence levels has been echoed by the United States Renal Data System 
(USRDS) findings, which demonstrates a rapid rise in ESRD cases with diabetes listed as the 
Country Study Subject 
population 
Age of subjects  Definition 
of CKD 
Australia AUSDIAB 11,247 >25 CKD 1-5 
D.R. of Congo Sumaili et al 503 >20 CKD 1-5 
Norway  HUNT 2 65,604 >20 CKD 3-5 
South of China Chen et al 6,311 >20 CKD 1-5 
UK HSE 2010 6,000 >16 CKD 1-5 
USA NHANES IV 13,233 >20 CKD 1-4 
Pakistan Jessani et al 2,873 >40 CKD 3-5 
Eastern China Xue et al 14,399 >18 CKD 1-5 
Nigeria  Stanifer et al 5,005 >20 CKD 1-5 
Republic of Ireland Austin et al 278,630 >18 CKD 3-5 
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primary cause since the 1980’s (Atkins, 2005). Although, recent figures now show a gradual 
decline in numbers from 2010-2012 (Figure 1.2a). Similarly, the rate of new ESRD cases has 
declined since 2006, with the lowest rate in 2012 since 1997 (Figure 1.2b).  
Figure 1.1 Number of individuals with an eGFR below 60ml/min/1.73m2  
  
 
 
 
 
 
 
 
(Adapted from: Roth et al., 2011. Kidney disease and renal function. Figure 8C). 
Studies have also begun to highlight some of 
the striking differences in the CKD risk 
attributed to diabetes and hypertension 
amongst various ethnic groups. Compared to 
Caucasians, the prevalence of diabetic renal 
failure is two- to threefold greater in blacks, 
Asians and Hispanics, and up to 18-fold greater 
in Native Americans. Black race/ethnicity is 
also associated with more rapid progression of 
renal disease (Daugirdas, 2011). In the UK, 
these findings prove to be evident in people of 
south Asian ethnicity, where CKD stage 5 is 
approximately three times more frequent than 
in those of white ethnicity, mainly due to 
increased incidence of diabetes as well as renal 
dysplasia and almost all types of glomerular 
disease (Higgins, 2009). In the USA, the CARDIA 
study displayed a 2.4-fold increase of renal 
Figure 1.2 (a) Trends in ESRD Incident cases, and (b) 
Rate of new ESRD cases per million/year, by primary 
cause of ESRD, in the U.S. population, 1980-2012). 
(a) Number of CKD cases 
(b) Rate of CKD incidence 
(Retrieved from: Saran et al., 2015. US Renal Data 
System 2014 annual data report: epidemiology of 
kidney disease in the United States. Figure 1.7).  
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impairment odds in women and a ninefold increase in men when compared with Caucasians 
(Stehman et al., 2003). 
However, whilst the magnitude of CKD has been better defined in developed countries, 
increasing evidence indicates the burden of CKD is as great or even greater in developing 
countries. Disadvantaged communities, such as those from low resource, racial, and ethnic 
minorities and/or indigenous backgrounds, suffer from marked increases in the incidence, 
prevalence and complications of CKD (Kimmel and Rosenberg, 2015). In India, a population-
based study presented diabetic nephropathy to be the most common cause of ESRD, occurring 
in 44% of individuals. Findings also determined the average crude incidence rate of ESRD to be 
150 per million population and where CKD equalled cardiovascular disease as a cause of death 
in people with diabetes (Modi and Jha, 2006).  
The fact that even in developed countries racial and ethnic minorities display a disproportionate 
burden of the disease suggests there may be multiple other elements beyond traditional risk 
factors associated with CKD.  
One of the largest concerns surrounding CKD prevention is in fact disease awareness. Findings 
from the Kidney Early Evaluation Program (KEEP), a community-based study, revealed only 10% 
of the 26,213 participants were actually aware of suffering from CKD. Awareness levels were 
particularly low however in those with early CKD, with 5.1%, 6.3% and 10.0% for stages 1 to 3. 
Alternatively, almost 40% of stage 4 and 60% of stage 5 sufferers were aware of having kidney 
disease (Vassalotti et al., 2010).   
1.5 Risk factors of CKD  
Previous clinical and epidemiological research has shown key associations between numerous 
factors as well as the initiation and progression of CKD. Fundamentally, two well defined groups 
have been established: those that are causal to CKD (risk factors) and those that are associated 
with CKD in the absence of established causal relations (risk markers) (El Nahas, 2005). Presently, 
the relationship of these biomarkers and as to whether they are risk factors or risk markers for 
the progression of CKD is not well understood. Risk markers are not causally involved in CKD 
progression, however they may indicate the probability of progression and therefore could 
potentially be used as diagnostic tools. Risk factors causally affect disease progression and are 
therefore interesting therapeutic targets (Kronenberg, 2015). 
1.5.1 Aetiology and risk factors  
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Progression of most kidney diseases can be seen to take more than 10 to 15 years, initially 
without any symptoms. This can prove a difficult task when trying to identify the aetiology of 
disease. Many indications show that clinical and sociodemographic risk factors play a significant 
impact on the susceptibility and initiation of chronic kidney disease; this includes a higher risk in 
elderly populations (Stevens et al., 2010); those that have a family history of CKD such as 
autosomal dominant polycystic kidney disease (ADPKD) (Levey et al., 2003); racial factors as seen 
in Afro-Caribbean and Asian individuals and those that have a pre-existing disease such as 
diabetes mellitus, metabolic syndrome and cardiovascular disease (El Nahas and Bello, 2005).  
Established or suspected clinical and sociodemographic risk factors associated with the 
susceptibility or initiation of CKD are shown in Table 1.3: 
 Table 1.3. Risk factors associated with the initiation or susceptibility of chronic kidney disease  
Adapted from: Owiredu et al., 2012. Metabolic syndrome among Ghanaian patients presenting with chronic kidney 
disease.  
1.5.2 Progression of CKD 
The progression of established CKD is variable and depends on several risk factors or markers. 
Progression factors can be separated into two defined groups; traditional and novel (Figure 3.1). 
Traditional factors includes those that are already classically established towards the 
progression of CKD such as obesity, ethnicity, smoking, hypertension, and the presence of 
proteinuria (Kronenberg, 2009). Metabolic risk factors have also been implicated in the 
progression of CKD; this was made evident by the UK Prospective Diabetes Study in 2003 which 
identified the acceleration of diabetic nephropathy in type 1 and type 2 diabetes (Adler et al., 
2003).  
The severity and extent of renal complications in patients with CKD is disproportionate to the 
number and severity of traditional risk factors. As a result, this realisation has focused the 
importance of non-traditional risk factors including reduced haemoglobin levels, 
microalbuminuria, increased inflammation and oxidative stress, and abnormalities in bone and 
Age Nephrotoxins 
Gender Primary kidney disease 
Ethnicity Urological disorders 
Family history of CKD  Cardiovascular disease 
Diabetes Mellitus Dyslipidaemia  
Metabolic syndrome  High normal urinary albumin excretion 
Hyperfiltration state  Low birth weight  
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mineral metabolism. Nonetheless various studies in patients with advanced CKD have not shown 
that normalisation of these non-traditional risk factors improves survival rates. Moreover, the 
mechanisms by which these novel risk factors contribute to CKD risk are largely unexplored 
(Kendrick and Chonchol, 2008).Therefore, although current treatment of patients with CKD 
includes management of traditional and nontraditional risk factors, the value of modifying some 
nontraditional risk factors remains unclear. 
Hypertension                                            
With a global prevalence estimated at 
nearly 1 billion people, high blood 
pressure (defined as >140/90 mm Hg) is 
labelled as one of the major leading risk 
factors for development and 
progression of CKD (Bakris and Ritz, 
2009). The aging population of the world 
coupled with increased prevalence of 
obesity and type 2 diabetes provides a 
platform for increased levels of 
hypertension within populations; so 
much so that figures have been 
estimated to rise to 1.56 billion sufferers 
by 2025 (Kearney et al., 2005). For many 
years now hypertension has been 
established as both a cause and 
consequence of CKD (Klag et al., 1996; 
Jafar et al., 2003) and is also shown to 
increase the risk of ESRD (Chapman et 
al., 2010). Supported theories for the suggested development of hypertension in CKD includes 
the activation of the renin angiotensin aldosterone (RAAS) pathway, abnormal mineral 
metabolism which effectively leads to arterial stiffness, sympathetic activation, and alterations 
to water and salt handling with sodium and water retention (Chan, 2012). Aside from these 
causes, studies have also indicated a strong relationship between blood pressure and 
proteinuria in hypertensive CKD patients; this was made evident from the Modification of Diet 
in Renal Disease (MDRD) study whose findings indicated the importance of hypertension control 
in patients with proteinuria higher than 1 g/day. By lowering blood pressure to a target of 
Figure 1.3 Traditional and novel risk factors for the 
progression of chronic kidney disease. 
(Adapted from: Kronenberg, 2009. Emerging risk factors and 
markers of chronic kidney disease progression. Figure 1).  
Traditional progression factors or markers: 
 African American ethnicity 
 Proteinuria 
 Hypertension  
 High protein intake  
 Obesity  
 Anaemia 
 Dyslipidaemia 
 Smoking  
 Nephrotoxins 
 Cardiovascular disease  
 Diabetes Mellitus (type 1 and 2)  
 
Progression 
of CKD: GFR 
decline + 
ESRD 
 Novel progression factors or markers: 
 Oxidative stress 
 Inflammation  
 Endothelial dysfunction 
 Vascular calcification  
 Insulin resistance 
 Uremic toxins 
 Coagulation disorders  
 Atherosclerotic plaque 
 Metabolic acidosis  
 Lead or heavy metals 
 Low birth weight or prematurity 
 Disorders of bone and mineral metabolism. 
 Electrolyte imbalance  
 Sleep disturbances 
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125/75 mm Hg, a greater decrease was achieved in the rate of decline of GFR than in those with 
less proteinuria (Klahr et al., 1994). Likewise, it can also be said that proteinuria is exacerbated 
by frequently increased blood pressure, resulting in the promotion of tubular atrophy, fibrosis, 
and tubulointerstitial inflammation and thus further elevating BP (Toto, 2005).  
Dyslipidaemia  
Irregularities in lipid metabolism, coupled with alterations in lipid profile, are seen to be a 
common occurrence in patients with CKD. These abnormalities tend to occur in the earliest 
stages of kidney disease and consequently lead to a decrease in glomerular function (Kowalski 
et al., 2015). Studies investigating the disorder of lipid metabolism in CKD patients have 
identified a significant increase in triglycerides (TGs), total cholesterol and low density 
lipoproteins (LDL) (Parmar et al., 2014). Reasons for this are suggested by the down regulation 
of lipoprotein lipase and abnormalities within the lipoprotein profile which ultimately leads to a 
reduction in receptor binding and lipoprotein uptake. Additional metabolic defects result in an 
increase of very low density lipoproteins (VLDL) and apolipoprotein B (ApoB)-rich lipids (Kaysen, 
2006). Combined with a decrease in high density lipoproteins (HDL), these defects prove to 
generate a highly atherogenic profile within CKD patients and therefore vastly escalate the risk 
of CVD outcome (Tannock, 2015). Considering the fact that patients with CKD are amongst the 
highest risk for CV-related events, the decision to implement specific recommendations 
regarding dyslipidaemia in CKD patients was put forward by the Kidney Disease Outcomes 
Quality Initiative (K/DOQI) (The National Kidney Foundation, 2003). The outcome suggested a 
strong agreement towards the management and importance of dyslipidaemia in patients with 
kidney disease. However, recent trials have displayed only a modest benefit in dyslipidaemia 
treatment with regards to cardiovascular mortality, therefore indicating a need for further study 
(Afsar, 2013). 
Diabetes mellitus  
In the UK alone, over 3.2 million people are affected by diabetes, equating to 6% of the total 
population (Diabetes UK, 2015). Diabetes has long been regarded as the most common single 
cause of end-stage renal disease in both the US and Europe (Molach et al., 1998). A considerable 
increase in diabetes prevalence amongst populations, mainly due to the rising trend in lifestyle 
habits and westernised cultures, has meant that diabetic nephropathy is now more common 
than ever; with 40-50% of type 1 and type 2 diabetic patients being affected (Gross et al., 2005). 
Increased risk of death, mainly from cardiovascular causes, is present in diabetic patients with 
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microvascular disease and is defined by increased urinary albumin excretion (UAE) in the 
absence of other renal diseases. Morrish and colleagues reported that kidney disease accounted 
for 21% of deaths in type 1 and 11% of deaths in type 2 diabetes (Morrish et al., 2001). Early 
indications of nephropathy are marked by the presence of abnormal albumin levels within the 
patient’s urine (>30mg/day), also known as microalbuminuria (Table 1.4) (Bennett and Aditya, 
2015). Without specific interventions, progression to overt nephropathy, or macroalbuminuria 
is heralded by a UAE of >300mg/day, sufficiently leading to a progressive decline in glomerular 
function rate and hypertension (Gross et al., 2005). Initially, studies from the 1980’s had 
demonstrated that around 80% of microalbuminuric type 1 diabetic patients progressed to 
proteinuria over a period of 6-14 years (Mogensen and Christensen, 1984). However, in more 
recent times, studies have showed only 30-45% of proteinuria progression in these patients over 
10 years (Caramori et al., 2000). Suggestions are favoured by the more intensive glycaemic and 
blood pressure control strategies that have been implemented over the years.  
Table 1.4 Interpretation of various proteinuria measurement tests  
 Normal High Very high 
Albumin creatinine 
ratio (mg/mmol) 
< 3 3-30 >30 
Urinary albumin 
excretion (mg/day)  
< 10 10-300 >300 
Urine diptest -ve to trace Trace to 1+ >1+ 
Adapted from: Stringer, 2013. Establishing a high risk CKD cohort: Cross-sectional analysis and early outcomes. Table 
2. 
With regards to current diagnostic and prognostic strategies for type 2 diabetes, there are two 
tests which are commonly employed in the healthcare background; this includes the 
measurement of plasma glucose and glycated haemoglobin (HbA1c). Nevertheless, it goes 
without saying that these measures do not prove to be fool proof due to the biased nature of a 
number of clinical and analytical factors. Therefore, the introduction of other indices of glucose 
homeostasis in clinical practice such as fructosamine and glycated albumin (GA) may be 
regarded as a favourable alternatives, especially in those individuals that HbA1c may prove to 
be biased or even unreliable (Danese et al., 2015). Such patients include those with rapid 
changes of glucose homeostasis, individuals with red blood cell disorders and most importantly, 
in those with renal disease. In addition, further advantages of fructosamine and GA over HbA1c 
are represented by the lower reagent costs and being able to automate the biochemical analysis 
on many conventional laboratory instruments (Dingari et al., 2012). 
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As a consequence of the greater susceptibility to glycation of albumin and other plasma proteins 
compared to intracellular proteins such as haemoglobin, the blood levels of fructosamine exhibit 
a broader fluctuation than those of HbA1c, thus allowing an earlier detection of rapid changes 
of blood glucose. Accordingly, the measurement of fructosamine seems useful not only as an 
alternative index of glycaemic control in conditions in which HbA1c is unreliable , but also for 
identifying impaired control of blood glucose before any noticeable changes in HbA1c may occur 
(Roohk and Zaidi, 2008).   
Lifestyle factors   
It has long been known that lifestyle plays a significant role in the development and progression 
of CKD (Hallan et al., 2006). Diet, obesity and sedentary lifestyles have been recognised to be 
contributors towards the development of CKD and associated comorbidities. However it must 
be said that existing data of the link between dietary protein intake as an independent risk factor 
for the initiation and/or progression to CKD is sparse (Stengel et al., 2003). Nevertheless, studies 
into this contributing factor have consistently demonstrated a link between dietary protein 
intake and systemic blood pressure. One example was seen by De Miguel et al., 2011 whose 
research saw rats fed a high-protein (30%) diet from 5 to 12 weeks of age. The results produced 
significant data showing the highest increase in mean arterial blood pressure and urine albumin-
to-creatinine ratio when compared to normal and low-protein diets.  
Amongst the other lifestyle factors, physical inactivity leading to low exercise capacity is 
common in CKD patients and particularly those undergoing haemodialysis (HD) (Manfredini et 
al., 2012). Although a scarcely investigated focus, a recent study examining ‘Physical activity and 
energy expenditure in haemodialysis patients’, revealed a compatibility between the physical 
activity parameters of HD patients and a sedentary lifestyle. It was reported that inactivity in 
these patients was worsened by the presence of ageing, diabetes and higher BMI, thus 
suggesting a greater need for improved health training exercises and interventions in CKD 
patients (Avesani et al., 2012). 
Several epidemiological studies have attempted to identify the role of smoking and alcohol 
consumption in the development of CKD (perneger et al., 1999. Vupputuri and Sandler, 2003). 
Unsurprisingly, excessive alcohol consumption related to a four-fold risk in the development of 
renal dysfunction (Perneger et al., 1999). Reasons for this are suggested by the initiation or 
promotion of atherogenic risk factors such as hypertension, hyperuricaemia, insulin resistance 
and diabetes (Stengel at al., 2003). A study investigating the joint exposure of heavy drinking 
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and smoking in >4000 individuals found a five-fold association with the development of CKD 
when compared with their absence. Clearly the harmful effects from both smoking and drinking 
are demonstrated as potential factors towards the progression of renal failure. However, 
despite these findings recent studies have proven contradictory to this assumption; an 
investigation by Funakoshi et al., in 2012 showed an inverse association between the frequency 
of drinking alcohol and CKD in healthy Japanese men. Results showed that although regular 
alcohol consumers showed signs of increased hypertension to non-drinkers, this group had a 
lower prevalence of CKD and hyper-LDL-cholesterolaemia, as well as increased HDL-cholesterol 
and a lesser prevalence of diabetes to the non-drinkers group. Although not fully understood, 
suggestions are targeted towards the protective effect of alcohol by the mediation of increased 
HDL-cholesterol. (Schaeffner et al., 2005).  
The rising trend amongst obese populations is a common yet serious implication to today’s 
health system. With a reported prevalence of around a quarter of adults (26% of men and 24% 
of women) in the UK (Craig and Mindell, 2014), it is suggested that obesity may be a primary 
contributor towards the progression of CKD and ESRD (Mount et al., 2015; Tanner et al., 2012). 
However, it goes without saying that much of the additional risk for CKD observed in those with 
obesity is associated with the increased prevalence of type 2 diabetes and/or hypertension 
(Ejerblad et al., 2006). Early observations of this relationship between obesity and CKD can be 
seen from the Framingham heart study cohort in 1999. In this study, they reported increased 
levels of body mass index (BMI) which conferred with a higher risk of CKD, as detected by an 
elevated serum creatinine level (Culleton et al., 1999). Similar results were yielded by (Hsu et 
al., 2006) who found subjects with a BMI of more than 40kg/m2, i.e. severe obesity, were at a 
seven fold higher risk of CKD than those in the standard risk group with a normal BMI.    
The mechanics behind the exact cause of obesity-induced CKD are highly unexplored and 
extremely convoluted (Mallamaci and Tripepi, 2013). Ideas have been put forwards to suggest 
an interplay between the onset of inflammation, insulin resistance, hypertension and 
dyslipidaemia (Teta, 2010). More specifically, research has shown that a higher visceral fat is 
linked to increased levels of fasting plasma insulin and triglycerides, resulting in obesity-related 
glomerulopathy (Mount et al., 2015).    
 
Inflammation 
The rate of mortality is higher than expected in patients with CKD which can not only be 
explained by traditional risk factors such as diabetes, hypertension and dyslipidaemia but by 
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other factors including inflammation and predisposition to infection which are believed to have 
a significant contribution towards renal dysfunction and associated cardiovascular comorbidities 
(Chade et al., 2005). A range of inflammatory markers such as C-reactive protein and fibrinogen 
have been proposed as risk factors for both CKD and CVD (Rifkin and Sarnak, 2009), many of 
which are non-modifiable or causal, although recent studies show that treatment of 
inflammation in patients with increased C-reactive protein may in fact lower the risk of CVD and 
slow progression of kidney disease (Heidari, 2013). Moreover, the recent development of high-
sensitive CRP (hsCRP) has been known to indicate future vascular events in CKD patients, even 
in those with no previous history of CVD, therefore recommending this globular indicator as a 
more accurate and sensitive detector of inflammatory state (Kumar and Shobharani, 2015). 
Glomerulosclerosis as a result of renal tissue scarring has been proposed to greatly influence the 
outcome of CKD as this leads to the influx of monocytes, production of lipid-laden macrophages, 
increased presence of cholesterol and matrix expansion, resulting in fibrosis.  Biological studies 
suggest that inflammation plays a key role in the process of glomerulosclerosis and subclinical 
measures of the disease have been associated with kidney dysfunction. CKD along with signs of 
inflammation are commonly found together, with a high prevalence of C-reactive protein, 
fibrinogen and white blood cell count, and low albumin found in stages 3-5 CKD (Rifkin and 
Sarnak, 2009).   
Oxidative stress 
Amongst the many factors that affect the speed of renal decline, oxidative stress has been 
identified as a powerful effector on progression of CKD (Small et al., 2012). The onset of 
oxidative stress occurs due to disparities between oxidant formation and insufficient amounts 
of antioxidants as a defence mechanism of the body. Aside from playing a role in the link 
between CVD and CKD through inflammatory mechanisms and endothelial injury, oxidative 
stress is also responsible for the excessive production of angiotensin II, hyperglycaemia and 
proteinuria which causes further progression of CKD (Putri and Thama, 2014). In addition, the 
capabilities of oxidants allow for a varied number of cell components to become oxidised such 
as carbohydrates, proteins, lipids and nucleic acids which, as a result, induces further damage in 
the kidneys (Kao et al., 2009).  
In terms of biological risk markers for oxidative stress there are several oxidative products which 
have been highlighted as advantageous in the detection of disease, this includes oxidised-LDL, 
advanced glycosylation end products, and oxidised thiol components which have been known 
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to contribute towards the pathogenesis of CVD and inflammation in CKD patients with uraemic 
state (Sung et al., 2013). 
CVD in CKD 
For many years, the risk association between both cardiovascular and chronic kidney disease 
has been well established (Foster et al., 2008). Most importantly, findings suggest that estimated 
cardiovascular mortality rates are between ten to one hundred times higher in late-stage CKD 
patients when compared to sex-matched individuals in the general population (Thomas et al., 
2008). Despite little investigation into early-stage renal failure, recent studies have supported 
the hypothesis that CVD risk is also prominent in the initial stages of renal decline, thus 
reinforcing the need for earlier interventions in the healthcare system to help prevent and treat 
CVD in this high-risk population (Wright and Hutchison, 2009). Furthermore, there has been 
numerous documented studies which highlight the prevalence of cardiovascular risk factors in 
the general population which contribute towards CVD risk in CKD patients (Yamamoto and Kon, 
2009). In fact, the number of Framingham risk factors specific to CKD patients, far exceeds those 
with a normal renal function. 
Hypertension is a traditional cardiovascular risk factor which contributes towards the 
cardiovascular risk associated with CKD (Tedla et al., 2011). In 2005, Muntner and colleagues 
demonstrated the enhanced risk of new or recurrent cardiovascular events in individuals with 
stage 2-3 CKD. Interestingly, their findings displayed a much higher risk association between 
systolic blood pressure and cardiovascular death than both diastolic blood pressure and heart 
rate (Muntner et al., 2005). In contrast however, some reports have shown a U-shaped 
relationship which exists between systolic blood pressure and mortality, with high or low blood 
pressure indicating increased mortality rates in stage 5 CKD patients (Myers et al., 2010).  
Aside from hypertension, there is also well documented findings on the association between 
CVD risk and diabetes mellitus in CKD patients (Kanda et al., 2008). Moreover, in those with 
moderate to severe renal dysfunction, a lower fasting plasma glucose and/or glycated 
haemoglobin, correlates with an overall lower risk of all-cause mortality and a reduction in 
cardiovascular death (Suckling and Gallagher, 2012). A common complication which resides in 
CKD patients is the presence of left ventricular hypertrophy (LVH), this frequent illness is also 
deemed a cardiovascular risk determinant in those with reduced renal function and is thought 
to be initiated by preceding cardiorenal risk factors such as hypertension and anaemia (Di Lullo 
et al., 2015).  
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Although many of the traditional Framingham risk factors are present in those with CKD, there 
are also several novel cardiovascular risk markers that are unique to this specific population. 
This includes anaemia which is known to occur adverse cardiovascular outcomes in CKD patient 
(Virani et al., 2008). In addition, irregular serum phosphate levels, calcium-phosphate ion 
product, and parathyroid hormone levels are also regarded as independent CV risk factors in 
late-stage renal dysfunction (Thomas et al., 2008). Increased calcium-phosphate products as 
well as the aggregated dosage of oral calcium-based phosphate binders strongly correlates with 
the range and progression of arterial calcification in those with stage 3 and 4 CKD, thus resulting 
in clinical morbidity and mortality in these patients (Friedman, 2006).  
Likewise, inflammation is regarded as playing a role in mediating CV risk in in CKD (Silverstein, 
2009). Elevations in the markers of inflammation are often seen in CKD patients, with some 
studies showing correlations between C-reactive protein (CRP) and predictions of cardiovascular 
outcomes in CKD patients (Bazeley et al., 2011). A study by Menon et al,. carried out the 
investigation of samples from the Modification of Diet in Renal Disease study patients, involving 
the measurement of CRP concentration and analysing the relationship between long-term 
outcomes. During a 10 year median follow-up period, their findings showed all-cause mortality 
to be existent in 20% of patients and CVD mortality in 10%. Additionally, Increased CRP levels 
were shown to independently predict all-cause and CV mortality after adjusting for cofounding 
variables. Therefore leading to confirmation from the authors that elevated CRP levels are useful 
in the prediction of outcomes in CKD patients (Menon et al., 2005). 
 
1.6  Pathophysiology  
The pathophysiology of CKD is complex and in large part dependent on the primary cause 
(Parmar, 2002). After a primary acute or chronic insult occurs, such as in diabetic nephropathy 
or lupus nephritis, many common pathways are activated to perpetuate glomerular and 
tubulointerstitial injury (Bird and Walker, 2015).  
In the initial stages of CKD, the traditional risk factors for CVD act as triggers not only for initiating 
the deleterious modifications in the cardiovascular system, but also as promoters of CKD 
progression (Figure 1.4). In intermediary stages of the disease, the typical CKD phenomena 
involved in the pathogenesis of CVD, such as anaemia, mineral metabolic disorders, and 
systemic inflammation begin to install. In the later stages of CKD and dialysis phase, traditional 
risk factors, those inherent to uraemia, and new specific factors related to the ongoing dialysis 
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modality, work jointly (Bucharles et al., 2010). Systemic low-degree chronic inflammation plays 
a central role in the pathophysiology. Several myocardial alterations, especially those associated 
with fibrosis and vascular calcifications, occur, justifying many events of sudden death (due to 
cardiac arrhythmias) and congestive heart failure. Atherosclerotic damage in medium and large 
calibre arteries accounts for cerebrovascular accident, peripheral vascular disease, and 
abdominal aorta aneurysm (Bucharles et al., 2010).  
 
 
 
Upon renal injury and at the loss of functioning nephrons, the remaining nephrons lose their 
ability to autoregulate glomerular pressure, this results in the onset of systemic hypertension to 
the glomerulus. Subsequent elevations in intraglomerular pressure lead to tubular and 
glomerular hypertrophy. In addition to these processes, endothelial and podocyte cell injury, as 
a result of uraemia-associated vasculotoxic and inflammatory damage, induce local 
inflammation and fibrosis, thus further progressing glomerular decline (Lopez-Novoa et al., 
2011). 
Furthermore, the role of proteinuria (induced by increased intraglomerular pressure), is thought 
to be regarded as the pathophysiological link between interstitial, tubular and glomerular injury 
Figure 1.4. Overview of the pathophysiology and complications in patients with CKD 
(Adapted from: Bucharles et al., 2010. Assessment and management of cardiovascular disease in patients with 
chronic kidney disease. Figure 1).  
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(Cravedi and Remuzzi, 2013). The extent of proteinuria in glomerular disease correlates with the 
rate of kidney dysfunction. This is due to the reabsorption of filtered proteins by the 
tubuloepithelial cells which results in oxidative stress, as well as direct damage to intracellular 
lysosomal pathways and the release of chemotactic factors. Consequently, these processes lead 
to the promotion of tubulointerstitial inflammation and fibrosis through the enrolment and 
activation of macrophages (Fogo, 2007).  
In both the tubuli and glomeruli, increased synthesis and reduced degradation of the 
extracellular matrix ensues as a result of chronic inflammatory processes, with excessive 
tubulointerstitial accumulation. Subsequently, the formation of tubular atrophy, 
glomerulosclerosis and tubulointerstitial fibrosis cause further degradation of functioning renal 
mass, thus formulating an endless cycle of disease progression by increasing intraglomerular 
pressure and hypertrophy of the residual glomeruli (figure 1.5),  (Tonolo and Cherchi, 2014). 
Lastly, in addition to the preceding factors, angiotensin II is also regarded as playing an important 
role in the formation of renal artery stenosis (RAS) and is mechanistically involved in most of the 
disease pathways described above. Produced both locally and systemically in the kidney, 
angiotensin II exerts several endocrine, autocrine and paracrine effects in the body (Sahay et al., 
2012). This potent vasoconstrictor is able to increase intraglomerular pressure by preferentially 
increasing the efferent arteriolar tone and also enhances intracellular calcium activity in 
podocytes, causing cytoskeletal changes and altered podocyte function. Furthermore, 
(Adapted from: Edeling et al., 2016. Developmental signalling pathways in renal fibrosis.. Figure 1).  
Figure 1.5 Development of kidney fibrosis 
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angiotensin II causes various increases intubular expression of cytokines, chemokines and 
growth factors as well as stimulating oxidative stress, resulting in the upregulation of adhesion 
molecules and chemoattractants (Matsusaka et al., 2010). 
 
CVD in CKD pathophysiology 
Hypertension is regarded as a strong risk factor for the development of CKD. Nonetheless, the 
cause and effect relationship between the two can also be contrasted with regards to CVD; even 
in the early phases of disease progression, CKD can cause hypertension, which in turn, is likely 
to increase the risk of CVD in those affected (Gansevoort et al., 2013). This was highlighted by a 
Japanese study which identified the increased relationship between hypertension and CVD in 
CKD patients (Kokubo et al., 2009). Moreover, patients with early or advancing CKD have been 
found to display a higher prevalence of left-ventricular hypertrophy. Research has shown that 
around 50% of patients with an eGFR below 30ml/min/1.73m2 tend to develop left-ventricular 
hypertrophy, of which most consist of concentric hypertrophy (Ardhanari et al., 2014) 
Aside from hypertension, it is also thought that renal anaemia and increased vascular stiffness 
may play a pivotal role in the development of left-ventricular hypertrophy (Herzog et al., 2011). 
Expression of endothelial nitric-oxide synthase is downregulated, suggesting a possible 
mechanism for coronary endothelial dysfunction in the early stages of CKD. Histologically, left-
ventricular hypertrophy in CKD is characterised by myocardial fibrosis which is regarded as 
impairing contractility. The high prevalence of left-ventricular hypertrophy and the associated 
risk implications could possibly explain why the chances of sudden cardiac death are increased 
in those with CKD (Lullo et al., 2015.  
Other factors that may contribute towards the raised CVD risk in in CKD patients includes the 
increased activity of the renin-angiotensin system and sympathetic nerve activity in CKD 
(Schlaich et al., 2009). The production of superoxide, interlukin 6, and other cytokines is 
stimulated by angiotensin. In addition, the bioavailability of nitric oxide (which is involved with 
vascular smooth-muscle contraction and growth), platelet aggregation, and adhesion of 
leucocytes to the endothelium, are lowered. Combined, all these vasoactive factors cause 
disturbances to endothelial function (Favero et al., 2014).  
One of the most frequent complications of kidney disease is the development of vitamin D due 
to the impaired activity of the kidney enzyme 1 a-hydroxylase, which converts this precursor to 
the active hormone. Various studies have demonstrated the associations between vitamin D 
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deficiency and raised risk of CV events, suggesting that the vitamin D pathway may be involved 
in the modification of the cardiac structure and function (Bosworth and Boer, 2013). 
1.7 Complications 
The reduction of GFR enables a varied range of disorders in those with CKD, this includes volume 
overload, hyperkalaemia, metabolic acidosis and hyperphosphataemia (Wallia et al., 1986). 
Additionally, hormonal imbalances can lead to the development of anaemia and secondary 
hyperparathyroidism, accompanied by renal osteodystrophy and systemic dysfunction that 
develops in the uraemic syndrome, such as anorexia, nausea, fatigue, neuropathy and 
malnutrition (Tzanakaki et al., 2014).  
1.7.1 Sodium and water imbalance 
The maintenance of sodium and intravascular volume balance is commonly well preserved until 
GFR drops below 15 ml/min/1.73m2. Adaption to changing water intake does, however, begin 
to diminish in the kidneys as both the maximum dilution and concentration of the urine 
gradually declines during the course of CKD (hyposthenuria). As patients reach ESRD, urine 
osmolality remains constant at around 300 mOsm/l (isosthenuria) regardless of actual water 
volume intake. Consequently, physiological factors other than water intake, urinary dilution and 
urinary concentration determine the volume of excreted water, thus leading to the 
development of hypo- and hypernatraemia in CKD patients (Kovesdy, 2012).   
1.7.2 Potassium imbalance 
Increases in serum potassium levels are common amongst those with renal decline. With a 
reduction in GFR, potassium excretion is maintained by changes in residual nephrons that 
increase the efficacy of potassium excretion. As a result of this adaptive response, those with a 
reduced GFR of less than 15 ml/min/1.73m2 experience extrarenal handling of potassium, 
especially gastrointestinal excretion, which becomes critical in dispersing an acute potassium 
load (Hsieh et al., 2011).  
1.7.3 Metabolic acidosis 
Metabolic acidosis is a common complication of CKD and is a result of the inability of the kidneys 
to excrete the daily dietary acid load (Kraut and Kurtz, 2005). In the early stages of progressive 
renal disease, as the overall number of functioning kidney tubules decrease, the tubular 
functions of the kidneys are diminished thus influencing their ability to produce ammonia and 
resulting in reduced levels of hydrogen ion excretion and increased bicarbonate excretion. This 
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excretion of bicarbonate ions leads to the lowering of plasma HCO3-, subsequently causing 
metabolic acidosis. Additionally, the kidneys also lose the capacity to reabsorb these anions due 
to a loss in tubular function leading to further anion excretion Kraut and Madias, 2016). In order 
to maintain the neutrality of electrons, the kidneys retain chloride ions with each bicarbonate 
ion lost, therefore early CKD is associated with hyperchloraemic metabolic acidosis.  Overall, the 
anion gap remains uninfluenced due to the continual excretion of organic acids by the kidneys 
(Kovesdy, 2012).  
1.7.4 Calcium and phosphorus imbalance 
As a result of declining functional nephron mass, the excretion of phosphate becomes disrupted 
in the kidneys, leading to increases in serum phosphate levels. In order to compensate for the 
hyperphosphataemia, the parathyroid gland responds by increasing the release of parathyroid 
hormones (PTH) (Snively and Gutierrez, 2004). Subsequently, increased PTH levels have several 
effects on the kidneys. Firstly, absorption of calcium is increased, specifically in the ascending 
limb of Henle. Secondly, PTH also causes an increase in the excretion of phosphorus by blocking 
reabsorption in the proximal tubule as well as activating 1-hydroxylase which converts vitamin 
D to its active form: 1, 25 hydroxly vitamin D. Thirdly, PTH also acts on bone by increasing the 
release of calcium and initiating the activation and proliferation of osteoclasts (Thomas et al., 
2008). Once further renal mass is lost and GFR falls below 60 ml/min/1.73m2, regardless of the 
compensatory hyperphosphaturia, the eventual onset of hyperphosphataemia is sustained 
(Murphree and Thelen, 2010).  
1.7.5 Anaemia 
The onset of anaemia is almost a universal finding in patients with stages 3 to 5 CKD. The 
anaemia of CKD is commonly normochromic and normocytic in nature, occurring in 
approximately 50% of patients (Thomas et al., 2008). While CKD-associated anaemia can result 
from multiple mechanisms (iron, folate, or vitamin B12 deficiency; gastrointestinal bleeding and 
systemic inflammation), the most common cause of this complication results from decreased 
erythropoietin synthesis. Erythropoietin, which is essential in the growth and differentiation of 
red blood cells in the bone marrow, becomes compromised in CKD through the effect of tubular 
atrophy which generates tubulointerstitial fibrosis and thus resulting in anaemia (Babbit and Lin, 
2012).  
Additionally, CKD-related anaemia increases the levels of morbidity and mortality from 
cardiovascular complications (angina, left ventricular hypertrophy and worsening heart failure), 
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leading to further decline of renal function and the establishment of an endless cycle termed 
the “cardiorenal anaemia syndrome” (Singh, 2007).  
 
1.8 Early recognition, prevention and treatment of CKD 
The ability to recognise early disease onset is one that is highly desirable, primarily due to the 
interventions that can be established to aid the reduction of CV events or further progression to 
kidney failure in those affected (James et al., 2010). High prevalence of CKD along with the 
absence of disease indication, accessibly of laboratory testing, and the availability of treatment 
measures suggest that screening for CKD would be a valuable and worthwhile possibility in the 
clinical setting (Jaar et al., 2008). Nonetheless, it must be argued that the action of population-
based screening remains controversial (Saunders et al., 2015). Screening for markers such as 
proteinuria is one that is easy to undertake, efficient in CV risk prediction and may be more 
effective in defining a reduced GFR than the use of estimated glomerular filtration rate 
(Sandilands et al., 2013). However, data from a US study which used annual dipstick testing to 
evaluate proteinuria found that the procedure was not cost effective unless the test was limited 
to high-risk individuals (e.g. older population, hypertension or diabetes) (Garg et al., 2002). With 
this in mind, previous literature has highlighted the efficiency of albuminuria testing in young 
populations, which is one of the most commonly tested marker of CKD in this category. In 
contrast, a reduced eGFR has been found to occur more frequently in elderly people with the 
disorder, therefore suggesting that albuminuria and eGFR might have complementary roles in 
the screening of different age groups, and a combination of both variables could prove to be 
resourceful in the identification of individuals at high risk of progression to late-stage renal 
failure (James et al., 2010).  
Due to the high associations between inflammation and cardiovascular disease, markers such as 
high-sensitivity C-reactive protein (hs-CRP) and Interlukin-6 (IL-6) are regarded as powerful 
predictors of cardiovascular events and mortality in CKD patients (Samak et al., 2002). 
Furthermore, recent studies indicate that even early onset CKD patients may suffer from 
inflammation. Using data from the Cerebrovascular Diseases and Dementia in the Community 
of Ebersberg (INVADE) study, research has shown high levels of hs-CRP to predict the increased 
risk of vascular events in a CKD population. More specifically, out of the 3,166 participants, 724 
individuals (23%) were found to have CKD at baseline. After a 4 year follow up, it was found that 
precisely 204 (6.4%) individuals experienced a major cardiovascular event. As illustrated in figure 
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1.6, the majority of vascular events occurred in subjects with high hs-CRP/CKD, thus suggesting 
the inflammatory marker hs-CRP to be of great prognostic value (Jalal et al., 2012). 
Figure 1.6. Kaplan-Meier survival curves showing the rate of survival in CKD and non-CKD 
subjects. 
 
 
Initial management strategies for CKD involve the identification of reversible conditions (e.g. 
infection or autoimmune disease) that would be respondent to specific treatment measures and 
result in the maintenance or improvement of kidney function (Vassalotti et al., 2016). Regardless 
of the principal cause of renal decline, typical aims for all CKD patients involves the prevention 
of CV events as well as decreasing the rate of progression of the disease, thereby postponing or 
averting any related complications.  
With regards to treatment measures, hypertension is considered the mainstay of CKD 
management to aid in slowing renal decline and reduce CV risk. Studies have shown that risk of 
CKD progression and kidney failure is dramatically increased as blood pressure reaches beyond 
130/80mm Hg. Thus, current recommendations set the BP target levels of CKD patients between 
125-135/75-85 mm Hg. Although, current guidelines promote a goal of lower than the desired 
blood pressure in the general population (Drawz and Rosenberg, 2011).   
To help reduce further progression of declining renal function, angiotensin-converting-enzyme 
inhibitors are utilised (Baltatzi et al., 2011). The efficiency of such measures are best seen in 
proteinuric CKD and are therefore suggested as first-line treatment in this target group. The 
(Adapted from: Jalal et al., 2012.C-reactive protein as a predictor of cardiovascular events in elderly patients 
with chronic kidney disease. Figure 1).  
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collective results of 11 randomised controlled trials revealed the risk of kidney failure or 
doubling of creatinine concentration serum to be reduced by nearly 40% using an angiotensin-
converting-enzyme inhibitor when compared to other forms of antihypertensive drugs in CKD 
patients (Maschio et al., 1996). Additionally, in those with diabetic nephropathy, angiotensin-
converting-enzyme inhibitor exhibits clear benefits in reducing the risk of death, dialysis or 
transplantation, including a 20% reduced risk of doubled creatinine concentration (Lewis et al., 
1993). Findings in a similar population study also showed that targeting glycosylated 
haemoglobin (HbA1c), to less than 6% reduced the incidence of new cases of microalbuminuria 
in those with both type 1 and type 2 diabetes (Kuo et al., 2016).  
Non-pharmacological treatment measures involved with CKD care include the limitation of 
dietary sodium intake to an amount of less than 100mmol per day to help manage or prevent 
hypertension (Wright and Cavanaugh, 2010). The implementation of dietary protein restrictions 
is also employed in CKD treatment methods with results of meta analyses suggesting a decrease 
in kidney failure or death with severe reductions or very low protein intake (Bellizzi et al., 2016). 
However due to the risk of malnutrition and the need for additional monitoring, stark 
restrictions in protein consumption is generally not valued in patients with CKD (Stark et al., 
2011).  
Finally, there has been large increments of evidence that suggest obesity as being associated 
with the development of CKD, as well as the involvement in progression to kidney failure and 
mortality-related findings (Hall et al., 2014). Although, how much of these effects are facilitated 
by the complications of diabetes, dyslipidaemia and hypertension remains unclear. Weight gain, 
which is known to increase the risk of CKD even in patients with normal starting weight, is 
suggested to be avoided in the setting of renal decline. Whereas those who present as 
overweight are recommended as losing weight due to known benefits for dyslipidaemia, 
glycaemic control, and hypertension (Mallamaci and Tripepi, 2013).  
Table 1.5 Characteristics of studies evaluating the impact of interventions on a CKD 
population. 
Study, year Sample size, n Intervention Outcome 
Howden et al., 2013 90 Lifestyle intervention (Smoking 
cessation and physical activity 
Improved glucose and lipid 
metabolism. Reduced 
inflammation with 
improved endothelial 
function 
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Appel et al., 2010 1,094 Blood pressure control Lowered risk of CKD 
progression 
Modification of diet in 
renal disease (MDRD) 
study , 1989 
840 Nutritional intervention Controlled blood pressure. 
Reduced albuminuria and 
slowed progression of 
kidney disease 
Bolignano and Zoccali, 
2013 
2,013 Weight loss intervention  Decreased proteinuria. 
Increased GFR in obese 
patients and delayed 
progression to ESRD in CKD 
patients 
Adapted from: Cramer, 2004. A systematic review of adherence with medications for diabetes. Table 1. 
 
1.9 Aims and Objectives 
CKD, along with several associated diseases such as diabetes mellitus and hypertension are 
amongst those that are growing at an unprecedented rate (Levey et al., 2010). In addition, the 
associated cost implications along with related adverse outcomes of these diseases places a 
significant financial burden on the healthcare system (Kerr et al., 2012). As previously 
highlighted, declining renal function, even at the initial stages, is an important independent risk 
factor for cardiovascular disease, thus several researchers have confirmed that early detection 
of CKD is essential in preventing CVD morbidity and mortality (Locatelli et al., 2002). 
Consequently, the implementation of screening programmes for early diagnosis of CKD is 
imperative, especially in high risk populations due to the silent and unrecognised development 
of the disease (Kopyt, 2006). By detecting renal failure at the earliest stages of progression, this 
will allow for more time for the prevention and treatment of primary causes as well as initiation 
of intervention programmes to aid in slowing the development to end stage renal disease.  
The overall objective of this study is to assess and detect the prevalence of CKD risk factors in a 
general, non-clinical population in order to evaluate the significance of testing in an apparently 
‘healthy’ group of participants and identify those at a higher risk of developing the complications 
associated with CKD and related diseases. 
The specific aims of the study included: 
 To study the prevalence of known traditional and novel CKD related risk factors in a non-
clinical population.  
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 Examine the applicability of several predictive equations in the estimation of GFR for the 
stratification of CKD. 
 Investigate the relationships between key risk factors amongst different subgroups of 
the total study population.  
 Provide evidence in the need for further healthcare screening strategies to help identify 
early onset CKD. 
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2.1 Study Population and method of recruitment  
In this study, males and females aged over 18 years and with no existing history of chronic 
metabolic disease were recruited from the University of Lincoln population. The overall 
population was split into two age groups comprising of under 30 years and over 30 years of age. 
Healthy subjects were recruited using several methods; this involved gaining access to the 
‘Healthy Campus Week’ promotion put on for staff by the University. Additional methods of 
recruitment also involved mass-mailing to heads of Schools offering the opportunity to take part 
in the study. Younger participants were recruited through undergraduate research projects by 
the School of Life Sciences. Lastly, from the help of the Human Resources department, further 
recruitment was conducted via the Global Corporate Challenge event that offered participants 
the chance to monitor their general health over a 100 day period and witness any changes from 
a before and after perspective.  
To qualify for recruitment, participants’ must not be pregnant at the time of testing or have 
previously been diagnosed with diabetes, cardiovascular problems or kidney disease. Any 
participants with a clinically diagnosed disorder were informed to consult with the principal 
investigator. Due to the nature of the bioelectrical impedance device those with any fitted 
electrical devices, such as pacemakers, were asked not to partake in the study.  
All study protocols were approved prior to subject recruitment (see appendix A1) by the 
University of Lincoln School of Life Sciences Ethics Committee. Written informed consent was 
obtained from all study participants and secured in a locked cabinet with access only available 
to the primary researcher and supervisors. Additionally, each individual was assigned a unique 
participant number to warrant complete confidentiality against all study results.                                                            
2.2 Protocol for testing  
Testing on participants was carried out at the University of Lincoln Science Building and the 
Joseph Banks Laboratories. Subjects who met the pre-specified inclusion and exclusion criteria 
were provided with a brief description of the study (see appendix A2) and invited to attend a 
screening session. Eligible participants who provided informed consent to the study (see 
appendix A3) were given a participant information leaflet detailing a more in depth explanation 
of the study objectives, procedures, risks and benefits and contact information (see appendix 
A4). On the day of assessment, respondents would arrive to the research facility on the morning 
or afternoon of their allocated time slot. Prior to testing, individuals were seated and asked to 
fill out a lifestyle questionnaire (see appendix A5) and, if not yet completed, a study consent 
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form. Anthropometric and haemodynamic measurements were taken prior to blood sampling. 
Blood drawn during phlebotomy was for laboratory testing as described in the following 
sections. Details of materials and equipment used for testing can be seen in table 2.1 below: 
Equipment  Description  
Seca 217 stadiometer  Used to measure height (cm) 
Seca 770 scales Used to measure weight (kg) 
Seca tape measure  Used to measure waist and hip (cm) 
Boso Medicus Uno monitor Measurement of systolic and diastolic blood pressure (mm Hg) and heart 
rate  
Bodystat 1500MDD  Bioelectrical impedance analysis  
Bodystat 0525 Electrode pads (4 per participant)  
Folded hospital privacy screen Used for the privacy needs of participants during measurements  
 
2.3 Anthropometric measurements 
All anthropometric and haemodynamic measurements were taken in triplicate to achieve a 
mean value and increase overall reliability of results. 
 
Height and weight  
Body weight measurements were taken to the nearest 0.1kg and height was measured using a 
fixed stadiometer in all participants after removal of footwear. Body mass index (BMI) was 
calculated the following way: 
                                                          
                                                   BMI = Weight (kg)  
                                                               Height2 (m2)  
 
Waist and hip measurements 
With the participants standing upright behind a curtain, waist circumference (cm) was measured 
using a tape measure at the point of midway between the costal margin and the iliac crest in the 
mid-axillary line. Hip circumference (cm) was determined at the widest point around the greater 
trochanter. Waist-to-hip ratio (WHR) was calculated by: 
                                                           WHR= waist (cm) 
                                                                        Hip (cm) 
 
Body fat percentage  
Participants were required to lie in a rested supine position on the seated bench provided and 
asked to remove their right sock. Body stat electrodes were then placed along the individuals’ 
extensor retinaculum and extensor digitorum of both the right hand and foot. Age, height, 
weight and circumference measurements were entered into the machine as well as activity 
Table 2.1. Equipment used in the body composition phase of the study.  
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levels. Participants were again asked if any electrical implants were present on their body. Upon 
completion of testing, recruits were then able to place any footwear back on.  
 
2.4 Haemodynamic measurements  
 Blood pressure was obtained at each study visit using a ‘Boso Medicus Uno’ monitor, a fully 
automated oscillometric recorder which measures systolic and diastolic pressure as well as heart 
rate. Participants were seated in a resting supine position and measurements were recorded 
three times to achieve an average.   
2.5 Protocol for phlebotomy  
Phlebotomy  
All blood was taken by an experienced phlebotomist with adherence to the university’s ethical 
regulations. Due to concerns surrounding the fasting state of participants upon arrival, it was 
agreed that all participants would arrive in a non-fasting state as to prevent damage or injury to 
participants’ health and avoid unlawful practice. Blood was collected with participants’ in a semi-
recumbent position using a 4ml Becton Dickinson gold top serum separation tube vacutainer. 
Samples were then left to clot between 30-60 minutes before being transported to the 
laboratory for immediate separation and storage; this was necessary due to the rate of glycolysis 
whereby 7% of glucose is lost from the uncentrifuged sample per hour. All subjects were asked 
to be seated for a further 5 minutes before leaving the testing facility to monitor for any health 
implications. All materials necessary for the procedure are highlighted in table 2.2. 
 
 
 
 
 
Equipment  Description  
Becton Dickinson gold top 
serum separation tube 
vacutainer 4ml  
Tube container for participants’ blood samples (one per person)  
Syringe - 
Blood needle  -  
Brady MPB21 label printer Used to label samples with the participants’ unique ID code 
Tourniquet  -  
Cotton wool buds - 
Plasters  - 
Fast aid pre-injection swabs 
70% IPA alcohol  
Used in the sterilization of participants’ arm prior to blood taking 
Table 2.2. Equipment used for the phlebotomy procedure. 
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Sample separation and storage  
Sample separation was carried out using a Beckman Coulter Allegra X-15R centrifuge. All 
samples were centrifuged at 3000 rpm for 5 minutes at 20oC (acceleration and deceleration rate: 
9). Pipetted serum layers were placed in a labelled eppendorf tube and stored in the refrigerator 
at 4oc until required for biochemical analysis. Maximum storage time for this temperature was 
estimated at 72 hours before all glucose assays would become unascertainable. Additional 
samples from the same yield were stored at -20oc for future assay. All materials used during this 
stage are found in table 2.3 below. 
 
 
2.6 Biochemical assays   
All assays were performed on the Horiba ABX Pentra 400, an automated clinical chemistry bio 
analyser which allows for highly accurate photometric measurements of a variety of human 
biomarkers. Before sample testing, the machine was first calibrated using ABX Pentra Multical, 
a lyophilized human serum calibrator with chemical additives and materials of biological origin. 
The assigned values of the calibrator’s components were provided in the labelling, ensuring 
optimal calibration of appropriate Horiba SBX SAS methods on the Pentra 400 analyser. After 
reconstituting one vial of Multical with 3ml of deionised water, the sample is left to stand at 
room temperature for no less than 30 minutes. The vial is then slowly agitated, avoiding any 
formation of foam and then transferred into a sample cup via pipette.  
Further calibration of Horiba Pentra N control and P control also took place prior to testing. 
These were quality control products which consisted of lyophilized human serum with chemical 
additives and materials of biological origin added as required to obtain given component levels. 
One vial of each reagent was mixed with 5ml of deionised water and left to stand at room 
temperature for 30 minutes. Following this, the samples were slowly agitated and the required 
volume was aliquoted into the sample cups.  
Equipment  Description  
Plastic pipettes  Used to aliquot the samples into separate tubes  
Eppendorf tubes  Storage of samples until use (three per participant)  
Brady MPB21 label printer Labels to identify participant samples  
Virkon solution  Sanitise used or processed materials  
Rubber gloves  Prevent contact between researcher and blood samples  
Beko LC120W fridge freezer Used for storage of participants’ samples  
Beckman Coulter Allegra X-15R 
centrifuge 
Used for the centrifugation of blood tubes 
Table 2.3. Equipment used in the sample separation and storage phase.  
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Both the calibration and control reagents were placed into the correct position on the 
instrument sample tray and assigned a location within the machine.  
The procedures stated above were also repeated for the fructosamine and hsCRP calibration 
and control reagents which were then placed into the machine and assigned target values. Table 
2.4 details all necessary materials used in the biochemical testing stage. 
 
 
 
Parameters that were determined during the study include:  
2.6.1 Renal Function  
Serum Creatinine 
Creatinine measurements are used in the assessment of renal dysfunction. Increased levels of 
creatinine are evident in renal diseases and insufficiency with reduced glomerular filtration; 
urinary tract obstruction; decreased renal blood flow including congestive heart failure, shock 
and dehydration.  
 
Renal function was assessed using the Abx Pentra Creatinine 120 CP reagent. This substance is 
a diagnostic reagent for quantitative in vitro determination of creatinine in human serum and 
based on a kinetic method using alkaline picrate (Jaffe method).  
 
Estimated glomerular filtration rate (eGFR) 
Equipment  Catalogue reference number  
Deproteinizer CP  A11A01754 
Clean-Chem 99 CP A11A01851 
Multi Cal A11A01652 
Fructo Cal  A11A01680 
CRP HS Cal  A11A01983 
N Control  A11A01653 
P Control  A11A01654 
Fructo Control N A11A01681 
Fructo Control P A11A01682 
Low CRP Control  A11A01731 
Creatinine 120 CP A11A01933 
Glucose PAP CP A11A01668 
Cholesterol CP A11A01634 
Triglycerides CP A11A01640 
Fructosamine  A11A01679 
CRP CP  A11A01611 
Sample cup  (blue)  A11A01766 
Table 2.4. Equipment used in the biochemical testing of participants’ samples   
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The eGFR (in ml/min/1.73m2) was calculated using the Modification of Diet in Renal Disease 
study (MDRD) equation (Levey et al., 1999).  
 
eGFR = 186 x [Serum creatinine (µmol/L) / 88.4] -1.154 x age (years)-0.203 x (0.742 if female) x (1.210 
if black) 
Additional equations were calculated for comparison to the standardised eGFR equation: 
Cockroft-Gault  
A commonly used substitute marker for the estimation of creatinine clearance is the Cockcroft-
Gault (CG) formula. This method employs the participants’ weight and serum creatinine 
measurements to predict the level of creatinine clearance.  
 
eCcr = (140 – Age) x Mass (kilograms) x Constant 
                        Serum Creatinine (µmol/L) 
 
(Where Constant is 1.23 for men and 1.04 for women)  
CKD-EPI  
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is considered to 
provide a more accurate prediction of glomerular filtration rate (GFR), along with a lesser bias 
and greater accuracy (Levey et al., 2009).   
GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black] 
Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females 
and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum 
of Scr/κ or 1. 
2.6.2 Markers of glycaemic control  
Glucose 
Glucose assessment was carried out using Abx Pentra Glucose PAP CP reagent. Enzymatic 
determination of glucose was calculated using the Trinder method.  
Fructosamine 
Abx Pentra fructosamine test is a bi-reagent kit which includes reagents R1 and R2 (NBT 
reagent/buffer), which was added to the sample. The colorimetric assay was based on the ability 
of ketoamines to reduce nitrotetrazolium blue (NBT) in an alkaline environment. The speed of 
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formazan formation was directly proportional to the fructosamine concentration. The reaction 
speed was measured by automated photometry at 546nm.  
2.6.3 Lipid and Lipoproteins 
Total cholesterol  
Abx Pentra CP test is an enzymatic photometric test which determines the level of cholesterol 
after enzymatic hydrolysis and oxidation. The colourimetric indicator is quinoneimine which is 
generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic action 
of peroxidase (Trinders reaction). 
 
Triglycerides 
In the enzymatic triglyceride method, triglycerides are hydrolysed by lipase to free fatty acids 
and glycerol. The glycerol is phosphorylated with ATP in the presence of glycerol kinase, and 
the resulting ADP is coupled to the formation of pyruvate, which is reduced by NADH. 
2.6.4 Plasma markers of inflammation and endothelial function  
 
High sensitivity C-reactive protein 
C-reactive protein (CRP) is an acute phase protein which tends to increase concentration as a 
result of the inflammatory process, most notably in response to pneumococcal infections, 
histolyic disease and a variety of disease states. CRP is used as a marker or general diagnostic 
indicator of infections and inflammation, in addition to serving as a monitor of patient response 
to therapy and surgery.  
Abx Pentra CRP CP is a latex-enhanced immunoturbidimetric assay developed to accurately 
measure CRP levels in serum and plasma samples for conventional CRP ranges. When an 
antigen-antibody reaction occurs between CRP in a sample and anti-CRP antibody which has 
been sensitised to latex particles, agglutination results. This agglutination is detected as an 
absorbance change, with the magnitude of the change being proportional to the quantity of CRP 
in the sample. The actual concentration is then determined by interpolation from a calibration 
curve prepared from calibrators of known concentration.  
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2.7 Statistical Analysis  
Data entry and statistical analysis was performed on SPSS version 20.0. A two-tailed p value 
<0.05 was considered statistically significant. All categorical variables were first tested for 
frequencies to check for response ratios. Additionally, descriptive statistics were carried out on 
all continuous variables to give the overall characteristics of the data set as well as provide 
information of the distribution and normality of the scores using the Kolmogorov-Smirnov’s test.  
Analysis of normality revealed the data to be unevenly distributed and therefore it was decided 
to test all data as non-parametric. Additionally, due to the sample size of the data in this study 
it was likely that outliers would exert a dramatic effect upon the correlation coefficient, either 
resulting in obscurities to the r value or an underestimation of the true relationship. Therefore, 
it was agreed that a scatterplot would be used to check for any outliers in the data and where 
possible, the removal or recording of any offending values. With the case of any missing values, 
SPSS allows descriptives to be run whereby the percentage of values that are missing for each 
of the variables is highlighted. When dealing with missing data it was agreed that the ‘exclude 
cases pairwise’ option would be chosen, as this excludes the cases (persons) only if they are 
missing the data required for the specific analysis. Importantly, they were still included in any of 
the analyses where they had the necessary information.     
Measures of variability 
Standard deviation was used to quantify the level of variation around the mean value of the 
observations retrieved from the data set. A low standard deviation indicates that the data 
points tend to be close to the mean value of the set, while a high standard deviation indicates 
that the data points are spread out over a wider range of values. 
Correlation coefficient  
To assess the strength and direction between two variables, Spearman’s rank correlation 
coefficient (r) was calculated. An r value of 1.0 indicated a perfect positive correlation, a 
correlation of -1.0 indicated a perfect-negative correlation, and a correlation of 0 indicated a 
random, nonlinear relationship between the two variables. Output variables were interpreted 
using Cohen’s guidelines (1988); where a strong correlation was determined by a result greater 
than 0.8 and a weak correlation was determined by a result of less than 0.5.  
To indicate the percentage of shared variance between the two variables, ‘coefficient of 
determination’ was calculated. This test allowed for the proportion of fluctuation of one variable 
that is predictable from the other variable. The coefficient of determination was calculated by 
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squaring the r value. This result was expressed further by multiplying by 100 and giving the 
‘percentage of variance’.   
Comparison of means  
Parametric tests 
An independent samples t-test was carried out on the data set to test for differences between 
two independent groups on a continuous measure. This test allowed for the statistical testing of 
probability that the two sets of scores came from the same population.   
Non-parametric tests 
A Friedman Test was carried out for one-way repeated measures analysis of variance by ranks. 
After establishing a statistically significant difference amongst the three ranks, post-hoc testing 
was carried out including the Wilcoxon Signed Rank Test. Due to the involvement of two tests, 
a revised Bonferonni adjusted value was applied giving an alpha level of determined statistical 
significance of less than .025.  
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3.1 Socio-demographic and clinical characteristics of the study 
population 
Overall, a total of 186 participants were recruited for this study. Amongst these individuals, 64% 
were female with a mean age of 31 years. In comparison, 36% of the total population was male 
with a mean age of 27 years. Table 3.1 displays the main sociodemographic and clinical 
characteristics of the study population according to gender. Analysis of gender differences 
revealed that females had a significantly higher body fat percentage (p = <0.001) and heart rate 
(p = .006). In contrast, males were found to have a higher systolic blood pressure (p = <0.001) 
and waist to hip ratio (p = <0.001).  
Table 3.1 Socio-demographic and clinical characteristics of the study population according to gender. 
 
Clinical status Females Males Sig. 
 Mean [SD] (%) Mean [SD] (%)  
N 119 (64%) 67 (36%) - 
Age (years) 31 [12.8] 27 [11.2] .031* 
Ethnicity    
Caucasian (90.8%) (86.6%) .445 
Black (2.5%) (4.5%) “ 
Asian (6.7%) (9.0%) “ 
BMI (kg/m2) 24.9 [6.2] 24.8 [4.0] .864 
Systolic blood pressure (mmHg) 123 [13.2] 136 [13.0] <0.001* 
Diastolic blood pressure (mmHg) 79 [10.3] 80 [10.6] .548 
Heart rate (bpm) 76 [11.3] 70 [13.4] .006* 
Body fat%  31 [9.2] 17.6 [6.2] <0.001* 
Waist: hip  0.79 [.062] 0.90 [.086] <0.001* 
Family history of    
Heart disease (21.8%) (20.9%) 0.989 
Type 1 diabetes (4.2%) (6%) .548 
Type 2 diabetes (17.6%) (22.4%) .355 
CKD (3.4%) (10.4%) .138 
Stroke  (10.9%) (7.5%) .495 
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Anaemia (6.7%) (4.5%) .577 
Hypertension (33.6%) (31.3%) .893 
Smoker (10.1%) (17.9%) .173 
N, number of subjects; BMI, body mass index; bpm, beats per minute; mmHg, millimetre of mercury.                  
* = Statistically significant result 
3.2 Laboratory parameters 
Results from the analysis of biochemical components revealed two key significant differences 
between the gender groups. This includes a higher level of triglycerides in males (Mean = 1.2, 
SD = 0.58, P = 0.004), and a higher level of creatinine in males (Mean = 81, SD = 15.8, P = <0.001). 
However, although significant, these measurements were within the normal range for both 
genders (Table 3.2). 
 
Table 3.2 Laboratory parameters in the recruited participant population. 
 
Laboratory parameter  Females Males Sig. 
 Mean [SD] Mean [SD]  
 
Lipids 
   
Total cholesterol (mmol/l) 4.24 [.89] 4.1 [.86] .274 
Triglycerides (mmol/l) 0.98 [.47] 1.2 [.58] .004* 
 
Diabetes mellitus 
   
Glucose (mmol/l) 4.49 [.90] 4.69 [1.1] .181 
Fructosamine (µmol/l) 221 [29.6] 227 [40.0] .224 
 
Kidney  
   
Serum creatinine (µmol/l) 63 [13.3] 81 [15.8] <0.001* 
eGFR (mls/min/1.73m2) 111 [31.0] 113 [26.0] .661 
 
Inflammation  
   
High sensitive CRP (mg/l) 1.39 [1.9] 1.4 [2.1] .976 
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate (calculated using the modification of 
diet in renal disease formula). N = 119 for females and 67 for males.  
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3.3 Age comparisons  
Overall, age comparisons of the separate genders indicated several significant differences 
between the two groups. Results from the male gender category are displayed in table 3.3. This 
shows a slight increase in several parameters in the over 30’s group which includes; BMI (mean 
= 24 vs 26 over 30’s, p=0.114), diastolic blood pressure (mean = 77 vs 87, p=0.001), waist to hip 
ratio (median = 0.87 vs 0.93, p=0.016), and body fat percentage (mean = 16 vs 22, p=0.001). In 
contrast, several parameters also revealed increases in the under 30’s group, this includes; heart 
rate (mean = 72 under 30’s vs 65, p=0.042), glucose (mean = 4.8 vs 4.4, p=0.216), and serum 
creatinine (mean = 84.1 vs 71, p=0.004). Likewise, the female gender group also revealed similar 
results with the over 30’s category showing higher readings in; body mass index (mean = 24 vs 
27 over 30’s, p=0.004), diastolic blood pressure (mean = 76 vs 84, p=<0.001), and body fat 
percentage (mean = 28 vs 35, p=<0.001). Similarly, increases were also observed in the under 
30’s group, more specifically in the creatinine readings which showed a mean result of 
65ml/min/1.73m2 in comparison to the over 30’s which was observed at a mean of 
59ml/min/1.73m2 (table 3.4).  
Upon further analysis, several parameters showed results outside the boundaries of a healthy 
range. This included BMI which appeared to be higher in males and females aged over 30 (mean 
in males = 25, SD =7.2, mean in females = 26, SD =3.7), as well as body fat percentage which was 
substantially higher in females aged over 30 years (mean = 35, SD = 9.3, p = <0.001).  
Table 3.3 Age comparisons between the male study-population.  
 
 
Parameters Under 30 years Over 30 years Sig. 
 Mean [SD] Mean [SD]  
N 71 48 - 
BMI (kg/m2) 24 [5.0] 27 [7.2] .004* 
Systolic blood pressure (mmHg) 121 [12.4] 126 [14.0] .037* 
Diastolic blood pressure (mmHg) 76 [9.4] 84 [9.8] <0.001* 
Heart rate (bpm) 78 [11.3] 72 [10.6] .006* 
Body fat%  28 [7.8] 35 [9.3] <0.001* 
Waist: hip  0.8 [0.07] 0.79 [0.06] .443 
Total cholesterol (mmol/l) 4.2 [0.82] 4.3 [0.92] .397 
Females 
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BMI, body mass index; bpm, beats per minute; mmHg, millimetre of mercury; CRP, C-reactive protein; 
eGFR, estimated glomerular filtration rate (calculated using the modification of diet in renal disease 
formula). 
Table 3.4 Age comparisons between the female study-population.  
 
 
BMI, body mass index; bpm, beats per minute; mmHg, millimetre of mercury; CRP, C-reactive protein; 
eGFR, estimated glomerular filtration rate (calculated using the modification of diet in renal disease 
formula). 
Triglycerides (mmol/l) 0.98 [0.47] 0.97 [0.48]  .885 
Glucose (mmol/l) 4.6 [0.93] 4.3 [0.83] .036* 
Fructosamine (µmol/l) 224 [29.3] 217 [29.9] .203 
Serum creatinine (µmol/l) 65 [12.9] 59 [13.3] .018* 
eGFR (mls/min/1.73m2) 112 [29.3] 109 [33.6] .643 
High sensitive CRP (mg/l) 1.55 [2.1] 1.15 [1.6] .273 
Parameters Under 30 years Over 30 years Sig. 
 Median [percentile] Median [percentile]  
N 50 17 - 
BMI (kg/m2) 24 [4.1] 26 [3.7] .114 
Systolic blood pressure (mmHg) 135 [12.8] 139 [13.9] .388 
Diastolic blood pressure (mmHg) 77 [10.2] 87 [8.6] .001* 
Heart rate (bpm) 72 [13.8] 65 [10.8] .042* 
Body fat%  16 [5.9] 22 [5.2] .001* 
Waist: hip  0.89 [.09] 0.93 [.07] .056 
Total cholesterol (mmol/l) 4.0 [.86] 4.3 [.85] .330 
Triglycerides (mmol/l) 1.2 [.55] 1.1 [.67] .574 
Glucose (mmol/l) 4.8 [.99] 4.4 [1.2] .216 
Fructosamine (µmol/l) 232 [41.3] 212 [32.3] .076 
Serum Creatinine (µmol/l) 84.1 [15.1] 71 [14.2] .004* 
eGFR (mls/min/1.73m2) 111 [24.8] 116 [30.0] .504 
High sensitive CRP (mg/l) 1.47 [2.24] 1.19 [1.5] .630 
Males 
Page | 43 
 
3.4 Analysis of kidney function  
To ascertain the associations between kidney function and the measured parameters, a Mann-
Whitney U test was performed on the split-gender population. Results from the analyses 
revealed similar outcomes with several biochemical parameters becoming significantly 
correlated with kidney function. In the male population, serum glucose (r = -0.555, p = <0.001), 
cholesterol (r = -0.475, p = <0.001), triglycerides (r = -0.436, p = <0.001), and fructosamine (r = -
0.427 p = <0.001) results revealed a strong negative correlation with eGFR. These results imply 
that as eGFR decreases, the biochemical parameters increase (table 3.5). Similarly, table 3.6 
shows results from the female population which indicates a strong negative correlation between 
the same biochemical parameters and eGFR as shown in the male gender group. Results include; 
serum glucose (r = -0.541, p = <0.001), cholesterol (r = -0.618, p = <0.001), triglycerides (r = -
0.422, p = <0.001), and fructosamine (r = -0.488 p = <0.001). Additionally, significance was also 
observed between waist to hip ratio and eGFR (r = -0.354, p = <0.001). 
Table 3.5 Spearman correlation coefficients between eGFR and the correlated variables in the male 
participant population 
 
 
Variable 
eGFR 
Correlation 
coefficient (r) 
Sig. 
Percentage 
variance (%) 
Age  -.009 .944 .008 
Waist:hip -.212 .085 4.5 
BMI (kg/m2) .015 .906 .023 
Systolic (mmHg) -.148 .233 2.2 
Diastolic (mmHg) .099 .427 0.99 
Heart rate (bpm) -.051 .680 0.26 
Body fat % .004 .973 .002 
Glucose (mmol/l) -.555 <0.001* 30.1 
Cholesterol (mmol/l) -.475 <0.001* 22.6 
Triglycerides (mmol/l) -.436 <0.001* 19 
Fructosamine (µmol/l) -.427 <0.001* 18.2 
hsCRP (mg/l) .061 .624 0.37 
BMI, body mass index; bpm, beats per minute; mmHg, millimetre of mercury; CRP, C-reactive protein; 
eGFR, estimated glomerular filtration rate (given as ml/min/1.73m2). 
 
Males 
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Table 3.6 Spearman correlation coefficients between eGFR and the correlated variables in the female 
participant population. 
 
 
BMI, body mass index; bpm, beats per minute; mmHg, millimetre of mercury; CRP, C-reactive protein; 
eGFR, estimated glomerular filtration rate (given as ml/min/1.73m2). 
 
Post hoc testing revealed a strong level of association between eGFR and glucose, with a 
percentage variance level of 30.1% in males and 29.3% in females. The relationship between 
glucose and eGFR is illustrated in figure 
3.1, this shows a strong negative 
correlation between the two variables. 
Likewise, fructosamine indicated a strong 
level of correlation against eGFR (figure 
3.2), with a percentage variance of 23.8% 
in the female population. However, a 
more scattered distribution of results is 
evident in the males which is reflected by 
the decreased percentage variance of 
18.2%.  
Variable 
eGFR 
Correlation 
coefficient (r) 
Sig. 
Percentage Variance 
(%) 
Age  -.045 .628 0.2 
Waist:hip -.354 <0.001* 12.5 
BMI (kg/m2) .113 .220 1.3 
Systolic (mmHg) -.136 .141 1.9 
Diastolic (mmHg) .081 .379 0.66 
Heart rate (bpm) -.165 .072 2.7 
Body fat % -.013 .891 0.02 
Glucose (mmol/l) -.541 <0.001* 29.3 
Cholesterol (mmol/l) -.618 <0.001* 38.2 
Triglycerides (mmol/l) -.422 <0.001* 17.9 
Fructosamine (µmol/l) -.488 <0.001* 23.8 
hsCRP (mg/l) .037 .693 0.14 
Females 
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Figure 3.1a Correlation between eGFR and serum 
glucose levels in males and females. 
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Analysis of the lipid-based parameters 
showed high significance between eGFR. 
The percentage variance of cholesterol in 
female participants was particularly high at 
38.2% which is illustrated by a strong 
negative correlation in figure 3.3. Although 
lower, males showed a significant 
correlation between cholesterol and eGFR 
with a percentage variance figure of 22.6%. 
In comparison to cholesterol, triglycerides 
were established to show a much lesser 
relationship between eGFR in both males (% 
var = 19% ) and females (% var = 17.9%). 
Nonetheless, a slight negative correlation 
can still be identified, therefore indicating a 
causal relationship between the two factors 
(figure 3.4).  
3.5 Comparisons between 
kidney equations  
To evaluate the contrast between several 
creatinine-based GFR estimation equations, 
a Friedman test was carried out. 
Investigations revealed a statistically 
significant difference between the three 
equations (MDRD, Cockcroft-Gault, CKD-
EPI), (n = 186, p = <0.001). Further inspection 
of the median values also showed Cockcroft-
Gault as having the highest estimation of 
kidney function (median = 
125ml/min/1.73m2, percentile = 100-161), 
followed by CKD-EPI (median = 
111ml/min/1.73m2, percentile = 97-123), 
Fructosamine 
(µmol/l) 
e
G
FR
 (
m
l/
m
in
/1
.7
3
m
2 )
 
Figure 3.1b Correlation between eGFR and serum 
fructosamine levels in males and females. 
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Figure 3.1c Correlation between eGFR and serum 
cholesterol levels in males and females. 
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Figure 3.1d Correlation between eGFR and serum 
triglyceride levels in males and females. 
 
Figure 3.1. Results from the Spearman rho tests showing 
scatterplot graphs between eGFR and several biochemical 
parameters including glucose, fructosamine, cholesterol 
and triglycerides with lines of best fit. 
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and MDRD (median = 105ml/min/1.73m2, percentile = 91-123). The differences between the 
three variables are illustrated in figure 3.5.   
Although the results indicated a significant difference between the equations, this does not 
describe where the differences lie. To explore the relationship further, post-hoc testing was 
carried out using individual Wilcoxon Signed Rank Tests. Additionally, to control for type 1 
errors, a Bonferonni adjusted alpha value was calculated (p = 0.017). Results from the post-hoc 
tests are displayed in table 3.7. Findings revealed a statistically significant difference between 
Cockcroft-Gault and MDRD (p = <0.001) with a medium to large effect size (r = 0.47), as well as 
Cockcroft-Gault and CKD-EPI (p = <0.001, r = 0.43), however due to the adjusted alpha value of 
0.017, MDRD and CKD-EPI were not reported as statistically different from one another (p = 
0.044) and only showed a small effect size between the two equations (r = 0.11). Upon further 
inspection of the mean rank values, Cockcroft-Gault gave the highest level of results with a mean 
rank of 2.51. In contrast, the CKD-EPI equation showed an intermediate set of results with a rank 
value of 1.95. Lastly, the MDRD equation revealed a score towards the lower end of the rankings 
at 1.54. 
Figure 3.2 Error bar graph showing comparisons between the MDRD, Cockcroft-Gault and CKD-EPI 
equations in the total study population. 
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Table 3.7 Wilcoxon Signed Rank Test of the three kidney function equations  
Sample 1 – sample 2 Z sig. r 
Cockcroft-Gault – MDRD -9.001 <0.001 0.47 
CKD-EPI – MDRD -2.017 0.044 0.11 
CKD-EPI – Cockcroft-Gault  -8.360 <0.001 0.43 
*Bonferonni adjusted alpha value = 0.017 
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Chapter 4.0           
Discussion 
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4.1 Study Review 
The diagnosis of chronic kidney disease is now relatively straightforward. However, the 
proportion of patients with end-stage renal disease who are assessed for the first time by 
nephrologists prior to initiation of dialysis is still unacceptable. Timely diagnosis and immediate 
referral are significant steps in CKD management. Consequently, this would allow for the 
implementation of preventative measures which delay or even halt the progression of CKD as 
well as decrease initial morbidity and mortality (Bastos and Kirsztakn, 2011). In this multifactorial 
research study of a mixed-aged, non-clinical population, it was found that several of the key 
predictors including age, BMI and blood pressure, showed a weak relationship between a 
reduced kidney function. However, anaylsis of several traditional biochemical parameters 
including serum glucose, fructosamine, cholesterol and triglycerides revealed a strong negative 
correlation between eGFR, meaning, as kidney function decreased, these parameters increased.  
As previously stated, the initial aims of this study was to investigate the prevalence of CKD risk 
markers in a non-clinical, general population and to determine the relationships between 
several key  parameters such as traditional and novel risk markers, whilst also establishing 
whether these relationships vary in different groups. It was therefore hypothesised that there 
would be a significant difference between gender and age groups with regards to kidney 
function, with high-risk individuals/populations presenting an increased level of well-known and 
established risk markers when compared to the low risk groups.  
4.2 Findings and implications 
 
4.2.1 Gender comparisons 
To evaluate the relationships between the study parameters, a gender comparison assessment 
was carried out. This allowed for the investigation of gender-influence and identify whether 
males and females should be separated prior to further examination of the study results. As 
expected, a comparison between the sexes of the participants (table 3.1) revealed a strong 
diversity in several body composition measurements. This included a significant difference in 
the haemodynamic results which showed a higher median value of systolic blood pressure in the 
male population. Reasons for this are supported by Dubey et al., and Reckelhoff who highlighted 
the key differences in male and female blood pressure due to hormonal and physiological 
differences (Dubey et al., 2002. Reckelhoff, 2001). Their findings revealed a higher proportion 
of pre-menopausal females with a lower arterial blood pressure than age-matched men. Similar 
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findings were also observed by Khoury et al., who’s study on a Danish population of 352 
normotensive adults, showed men were found to have a higher 24-hour mean blood pressure, 
by approximately 6 to 10 mm Hg, than did women up till the age of 70 to 79 years (Khoury et al., 
1992). As previously discussed, the strong relationship between CKD and hypertension has been 
shown prospectively in men. A study investigating nearly 12,000 hypertensive male veterans 
found that the relative risk of end-stage renal disease for pretreatment systolic BP of 165-180 
mmHg was 2.8 times higher and 7.6 times higher in those with a systolic BP greater than 180 
mmHg, when compared to a systolic BP of less than 140 mmHg (Perry et al., 1995).  
Amongst the differences displayed between the two gender groups, body fat percentage was 
the most highly foreseen. Freedman et al., 1990 displayed these differences in genders through 
the measurement of proportions in body fat. As with their findings, the results from this study 
showed men to have a lower overall body fat percentage when compared to women. However, 
these findings are not unexpected as it has been well established that women generally have a 
higher percentage of body fat than men (Vella and Kravitz, 2002). Fat in normal women tends 
to represent between 21-33% of body weight, this is reduced in men however, where fat only 
represents 10-22% of body weight (Blaak, 2001).  
Biochemical parameters  
It has long been recognised that serum lipids may contribute towards CKD progression, with 
previous studies reporting both hypertriglyceridaemia and low high density lipoprotein (HDL) 
cholesterol as independent risk factors for renal failure (Kurella et al., 2005). As highlighted in 
the beginning of this thesis, dyslipidaemia and abnormalities in lipid metabolism are known to 
contribute towards glomerulosclerosis and are common in renal disease (Kumar et al., 2014). 
Results of the present study partially confirmed the differences in lipid profile between both 
sexes as men were found to have a higher triglyceride value (1.07 mmol/l) when compared to 
women (0.86 mmol/l). Reasons for the higher values in males are suggested by the limited 
number of male participants that took part in the study (36%), therefore a more equal ratio of 
men and women may have reduced the overall outcome and produced more reliable readings. 
Nonetheless, higher triglyceride levels are found to be more common in males as shown in a 
study by Seidell and colleagues who found men with higher triglyceride levels were also at a 
higher risk of CKD (Siedell et al., 1991). When compared to the female population, no 
associations were present between any of the serum lipids and CKD.  
As previously outlined, the accurate assessment of kidney function among CKD patients is 
essential for interventional and diagnostic aims. Due to the many disadvantages of using 
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creatinine clearance and other markers, it is vital that predictive equations are applied to 
estimate renal function (Coresh and Stevens, 2006). The importance in the role of renal 
equations can be seen from our results which indicates a higher level of creatinine in the male 
population (82 µmol/L) when compared to the females (66 µmol/L). Despite this, present 
knowledge tells us that the cause of higher readings in men is due to the increased muscle mass 
and therefore greater excretion of creatinine in the body (Baxmann et al., 2008). This is reflected 
in the estimated glomerular filtration rates of the study population which takes into account the 
age, race and gender of our participants, thus producing results which show a much closer 
relation in average kidney function between the two sexes (Males = 109 ml/min/1.73m2 and 
females = 103 ml/min/1.73m2). 
Overall, the present findings are indicative of a significant difference in both the body and 
biochemical results, thus providing the necessary evidence to split the groups by gender when 
investigating further readings. The splitting of gender groups allows for a more accurate set of 
results which are less misinterpreted simply due to the physiological differences of the 
population.  
 
4.2.2 Age comparisons 
Findings from the independent samples t-test on age comparisons (table 3.3 and 3.4) revealed 
a strong difference between body fat percentage and body mass index. The findings echoed that 
of previously defined literature, whereby increases in body fat and BMI are found with increases 
in age (Kalyani et al., 2014). One study investigating the interactions between age, BMI and body 
fat found BMI to progressively increase with age in women and plateaued between 40 and 70 
years in men (Meeuwsen et al., 2010). More interestingly, an earlier publication examining the 
effect of aging on body fat found there to be no further significant increases in body fat after 
the age of 40, reasons for which are due to the unaccountability of an increased BMI that 
commonly occurs at middle age due to decreases in organ metabolic rates and resting metabolic 
potential (Silver et al., 1993). The abundant increase in such factors raises the question as to 
whether stricter assessment criteria should be implemented in these age-related populations 
and investigated more vigorously, on the accountability that increased BMI and body fat results 
in a higher risk of CVD and CKD (Stenvinkel et al., 2013).  
Assessment of haemodynamic function in the differential age groups revealed an increase in the 
diastolic blood pressure of the over 30’s population when compared to the under 30’s (table 3.2 
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and 3.3). It is thought that age-related increases in blood pressure are a common occurrence 
and one that is monitored closely due to the high associations between hypertension and 
development of CVD risk (Benetos et al., 2000). Although increases were reported on diastolic 
bp, there were no significant differences observed in the systolic measurements between the 
two age groups. These findings prove contradictory to previous reports however which indicate 
a continuous rise in systolic bp with advancing age while a stabilization or decline is observed in 
diastolic bp (Tin et al., 2002). As an increase in diastolic bp is evident in both sexes, one would 
deviate from gender influenced results and suggest that these differences may have been 
observed due to an imbalance in the age ratios of the study population.  
Evaluation of serum creatinine between the age groups revealed a decreasing level of creatinine 
with age. One reason to support this finding is the associations between lower than normal 
muscle mass and reductions in dietary protein intake, both which are somewhat common with 
an aging population and can lead to falsely depressed serum creatinine levels (Odden et al., 
2009). Studies have suggested that the use of serum creatinine as an indirect filtration marker 
is limited by its biological and environmental variability ((Musch et al., 2006). Contrary to these 
findings however, some studies have reported conflicting evidence which states that serum 
creatinine steadily increases with age (Tiao et al., 2002). A study by Pottel et al in 2008, 
discovered a serum creatinine-age pattern which was constant between the ages of 20 and 70 
years. Nonetheless, it has been highlighted that covering such a broad age-range in a small 
sample size does not allow for the accurate determination of age-specific reference intervals 
(Pottel et al., 2008). 
 
4.2.3 Analysis of kidney function 
Body composition  
In relation to the anthropometric measurements (table 3.5 and 3.6) , results from the Mann 
Whitney U test revealed no significant relationships between kidney function and the body 
composition readings, aside from wait to hip ratio in women (sig = <0.001) . These finding are 
surprising due to the well documented outcomes of associations between BMI, blood pressure 
and waist circumference, which are known to be independently associated with CKD 
(Navaneethan et al., 2012 and Burton et al., 2011). One study investigating the influence of 
anthropometric measurements on renal function found the increases of anthropometric 
measurements to negatively affect kidney function, with BMI producing a more prominent 
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outcome. For this reason, it is suggested that individuals with increased anthropometric 
measurements should be monitored closely in terms of renal functions additional to 
cardiovascular risk factors (Koc et al., 2006). As with our results, the outcome of increased 
associations between WHR and eGFR only in females, may be explained by the lesser number of 
male participants who still show a weak but insignificant correlation between the parameters. 
Markers of diabetes 
Concerning the biochemical measurements, the diabetic parameters including serum glucose 
and fructosamine showed a strong negative correlation with kidney function.  As shown in 
figures 3.1 and 3.2, eGFR decreases as the measurements increase. Supporting evidence tells us 
that diabetic nephropathy is one of the most common outcomes from poor glycaemic control, 
resulting in reduced kidney function and even end-stage renal failure (Schrijvers et al., 2011). As 
previously outlined, hyperglycaemia causes capillary vasodilation as well as high glomerular 
hydraulic pressure, therefore leading to glomerulosclerosis and hypertension which causes 
further damage to the kidneys (Marre et al., 1999). Interestingly, an investigation into the 
benefits of glucose lowering therapy found that efficient glycaemic control reduces 
hyperfiltration and hence improved kidney function overall (Meeme et al., 2009). Considering 
that blood glucose levels are easily affected by caloric intake (Gannon and Nuttall, 2004), this 
study did not require fasting by participants prior to blood sampling. Subsequently, glucose may 
have been a poor marker at investigating kidney function. Despite this however, studies have 
highlighted the question around the need of an 8-hour fasting duration. Moebus et al, 
discovered higher mean blood glucose levels only in the first 3 hours after a caloric intake 
(Moebus et al., 2011). This observation was also in line with previous findings which stated that 
in nondiabetic individuals, blood glucose levels return to preprandial levels within 2-3 hours 
(Sindoni, 1946 and American Diabetes Association, 2001). 
Likewise, fructosamine levels were increased in those with a lesser renal function. As 
fructosamine levels are representative of glycaemic control over a two to three week period, 
this further cemented our findings and was consistent with previous reports (Vos et al., 2011). 
As testing was not conducted over a prolonged period, this marker was effective in portraying 
the glycaemic nature of our study population over a two to three week period. Although, it was 
debated whether more accurate assessment of glycaemic control may have been highlighted 
better using either glycated haemoglobin (HbA1c) or glycated albumin (GA) markers (Vos et al., 
2012)   
Lipids  
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Analysis of total serum cholesterol revealed a highly correlated relationship between kidney 
function with a percentage variance of 22.6% in males and 38.2% in females (Table 3.1 and 3.2). 
As to whether this relationship was caused by an increase in HDL or LDL cholesterol, it is 
unknown. The inability to ascertain and quantify between the two components was due to the 
limitations of the assay, however as discussed in chapter 1, it is well known that patients with 
impaired renal function exhibit significant alterations in lipoprotein metabolism, which in their 
most advanced form may result in the development of severe dyslipidaemia (Tsimihodimos et 
al., 2011). Moreover, several epidemiological studies have demonstrated HDL-cholesterol to be 
a negative risk factor for atherosclerosis (Anavekar et al., 2004. Weiner et al., 2004). As 
atherosclerosis shares a well-established relationship with CKD (Luczak et al., 2011), it is thus 
unsurprising that patients with CKD are found to exhibit reduced levels of HDL-cholesterol when 
compared to those with normal renal function (Olechnowicz-Tietz et al., 2013). Nonetheless, 
contradictory reports have demonstrated a null association of HDL cholesterol with ESRD in a 
CKD population, thus postulating the hypothesis that HDL particles are rendered dysfunctional 
in some manner in CKD (Zewinger et al., 2014). Dissecting the complex interplay of HDL 
cholesterol, as well as the size of particles, composition and function in CKD is one that requires 
further investigation using strong epidemiology designs (Boer and Brunzell, 2014). 
In CKD patients, hypertriglyceridaemia proves to be one of the most common quantitative lipid 
abnormalities (Attman et al., 2009). Studies investigating this relationship have demonstrated 
an increasing concentration of triglyceride-rich lipoproteins (VLDL, chylomicrons and their 
remnants) in the early stages of CKD (Tsimihodimos et al., 2011). In this study, triglycerides 
shared a similar result to that of cholesterol; with increases in triglycerides accompanied by a 
decrease in kidney function levels (figure 3.4). These findings are consistent with previous 
studies which highlight impaired renal function as exhibiting increased concentrations of 
triglycerides (Charlesworth et al., 2005). Interestingly however, some reports have identified the 
similar affects taking place, even in those with a serum creatinine within the normal limits (Fliser 
et al., 1998).This evidence thus suggests the need for further investigations into the role of fats 
in CKD, which may be key to early identification of forthcoming reductions in renal function.  
Inflammation  
Analysis of hsCRP results showed no significant relationship with kidney function. In comparison, 
previous studies have showed inconsistent findings in the relationship between inflammation 
and progression of kidney function in a general population (Stuvelling et al., 2003 and Shankar 
et al., 2011). The result of a significant association between the parameters was identified in the 
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PREVEND study (Prevention of Renal and Vascular End stage Disease) which identified a strong 
relationship between hsCRP and lower eGFR in a non-diabetic population (Fox et al., 2010). 
However, contrastingly, Shankar et al. (2011), Indicated that elevated levels of hsCRP were not 
associated with progression to CKD in a population-based cohort. Evidently, it is clear that this 
relationship is not yet fully understood. The potential mechanisms which are responsible for the 
associations between inflammation and renal function declines was explored by Nand et al., 
(2009) who found that raised levels of hsCRP were closely associated with poor outcomes due 
to interplay of a number of mechanisms such as lower haemoglobin, high incidence of 
cardiovascular disease, poor nutritional outcomes, and lower body mass index. In acute 
inflammation such as infection, CRP levels rise up to 50,000 times fold. It is therefore suggested 
that such possible outcomes may be explored further through a white cell count to identify those 
that are displaying such levels.   
 
4.2.4 Kidney equation comparisons 
As discussed previously, the current diagnosis, management, and evaluation of CKD routinely 
relies on estimates of glomerular filtration rate. In our study, we derived the eGFR of the 
participants using the Modification of Diet in Renal Disease (MDRD) study equation, based on 
age, race, gender and serum creatinine levels of the assessed individuals (MDRD). The prognostic 
value of this GFR estimation has been validated in various studies and populations (Levey et al., 
2009). However to compare the standard of validity, we tested the abilities of the MDRD 
equation against several others, including the Cockcroft-Gault (CG) study equation and more 
recent, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.  
As expected, we found that the CKD-EPI equation provided a more accurate assessment of renal 
function within our study population, this finding is non-surprising as it has been well established 
by recent studies that the CKD-EPI equation, based on the same demographic and laboratory 
variables as the MDRD study equation, has been shown to represent a far more accurate 
estimation than MDRD, even more so at higher values of eGFR (Levey et al., 2009 and Stevens 
et al., 2010).  
Analysis of figure 3.5 details the variations between the equations, with CG showing a much 
higher level of predicted kidney function and MDRD indicating an underestimation of function. 
Previous reports have commented on the limitations of CG and MDRD, primarily due to the fact 
they were developed on data from patients with reduced renal function. In comparison, the 
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CKD-EPI equation was developed to eliminate the weak points of the former, with the data set 
of the formula taken from many participants with normal GFR in the development process 
(Levey et al., 2009). 
Overall, it is fair to say that our results are consistent with other published investigations. A study 
by Matsushita et al., (2012) on more than 1 million participants spanning over 40 countries, 
discovered approximately one-fourth of participants who were reclassified to a higher eGFR 
category using the CKD-EPI equation in comparison with the MDRD study equation. Effectively, 
these results lowered the prevalence of CKD in 24.4% of the general population cohort. In 
addition, their findings also revealed a more accurate estimation clinical risk in both Asians and 
Blacks, even though reclassification is much less common in blacks than in whites or Asians  
Given the more accurate assessment of GFR estimates and better risk categorization, the use of 
the CKD-EPI equation would thus contribute to a more suitable provision of health care 
resources and more targeted prevention and management of CKD complications (Michels et al., 
2010). 
 
4.3 Study considerations 
 
4.3.1 Strengths of the study  
A number of strengths were evident from this study, starting firstly with the care that was taken 
to assess the population of the study. Specific inclusion and exclusion criteria was in place to 
ensure all data was effectively accurate and representative of a general population. 
Furthermore, past studies have focused towards a patient-specific population when 
investigating the effects of risk markers on CKD. Evidently, this study features a non-clinical 
population which separates the investigation from previous related cohorts. Fundamentally, this 
study has helped to raise the awareness of risk in participants that may be of a non-clinical 
nature, which due to the silent nature of kidney disease, is a primary concern in this population.   
Additionally, the collection and processing of blood samples was carried out in a structured and 
rigorous fashion and immediately processed as outlined by standard operating procedures. All 
routinely measured variables were carried out in a single operating laboratory whereby samples 
were stored and batch-analysed to minimise inter-assay variability.  
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Due to the cross-sectional nature of the study, we were unable to infer causality from the results. 
Despite this however, when observing aetiology, diagnosis and prognosis, observational studies 
prove to be much more valid than others such as randomized controlled trials (Jager et al., 2007). 
A strong feature or this study is that we were able to compare several frequently reported 
equations, both new and old, to estimate kidney equations in one heterogeneous cohort and 
establish which would stand as the most effective gold standard in modern clinical assessment 
of GFR (Michels, 2010). We were also able to study the influence of several clinical 
characteristics and their effects on the performance of the formulas by stratification on these 
parameters.  
Overall findings from the study revealed a strong relationship amongst the lipid and diabetic-
related variables in relation to kidney function. These findings were both expected and 
consistent with previous literature, further solidifying the strong relationship between these 
variables and their ability to predict progression of renal insufficiency.  
4.3.2 Study Limitations 
Study Design 
Although the data presented in this thesis is regarded as representative of a general non-clinical 
population, the cross-sectional nature of the study design only allows us to establish an 
association of several factors, but not causality (Kearns et al., 2013). Therefore, it would have 
been preferable to conduct a longitudinal study with multiple measurements of an extended 
period to confirm and modify the estimated prevalence of CKD risk markers (Ogna et al., 2016).In 
addition, it is well known that renal progression rates are influenced by participant 
characteristics (Jafar et al., 2003 and O’Hare et al., 2007), therefore when targeting possible 
resources for CKD risk, further consideration should be given towards the variations in rates of 
progression across populations.  
Clinical and biochemical characterization  
Carrying out accurate and reliable examination of body fat percentage is one that proves to be 
challenging to most researchers (Khaled et al., 1988). Due to the cofounding variability of 
participants’ health state at the time of processing, several influences can have an effect on the 
bioelectrical impedance assessment (BIA); this includes the individuals’ level of hydration, with 
several studies reporting as much as 2-5% decrease in body fat percentage of those that were 
dehydrated at the time of measurement (Girandola et al., 2013). This information can have a 
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substantial impact from a clinical perspective as patient knowledge of over or under estimated 
body fat could initiate or reinforce disordered eating patterns (Saunders et al., 1998). 
Additionally, reports have also signified the cofounding influence of other factors such as 
ethnicity, phase of menstruation and underlying medical conditions, on the reliability of the 
bioelectrical impedance assessment (Gleichauf and Roe, 1989). This evidence supports the 
inclination that BIA may not be the appropriate choice for body composition measurement 
unless specific calibration equations are developed for different groups participating in the study 
(Dehghan and Merchant, 2008).  
A general issue facing clinical laboratories is the stability of analytes during sample processing 
and storage (Heins et al., 1995). Lengthy contact of serum samples with cells is a common cause 
of spurious test results, mainly due to the ongoing metabolism of cellular constituents as well as 
active and passive movement of analytes between serum and cellular compartments (Boyanton 
and Blick, 2002). In this thesis however, we were mindful of the convoluted instability frequently 
associated with sample processing and therefore implemented a strategic handling process 
whereby fresh samples were rapidly transferred for serum separation and stored immediately 
to await further analysis. 
One limitation that was evident form this study involved the repeated freeze-thawing of sample 
specimens. Previous literature tells us that continual freeze-thawing cycles are known to affect 
the integrity of biological samples and, more notably, to induce conformational changes in 
proteins that may ultimately lead to aggregation and degradation (Bhatnagar et al., 2007). One 
study investigating freeze-thaw cycles on clinical markers found that freeze-thawing a sample 
more than twice could begin to compromise data quality by interfering with peak detection 
(Kang et al., 2013). A review of laboratory errors has revealed that at least 40% of errors are 
made in the pre-analytical phase of processing (Kang et al., 2013). Therefore, it is important to 
consider the influence of pre-analytical variables and how they should be considered as key 
factors for generating consistent experimental data. Further work would include monitoring and 
maintaining sample quality, as well as handling and controlling samples correctly (Sweep et al., 
2003). 
In terms of marker specificity, concerns were raised around the reliability of the marker for 
glycaemic control, fructosamine. As such, it was suggested that future work would perhaps 
implement a more accurate parameter such as HbA1c which is indicative of glycaemic control 
over a period of approximately 12 weeks in comparison to the 2-3 week period of fructosamine 
(Sacks, 2011). However, based on costing’s, length and complexity of procedures, and the 
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accountability for fructosamine to provide a clinically accessible measure, as well as staying 
consistent with the time frame of the 1-week diet diaries required by participants, it was 
determined that HbA1c would serve as unnecessary to this study (Cohen et al., 2003). In addition, 
uncertainties were placed around the specificity of hs-CRP as it has been reported that between 
20-40% of hs-CRP variability is related to genetic factors (Martinez-Calatrava et al., 2007). 
Furthermore, several clinical and environmental factors such as age, obesity, smoking, diet, and 
statin treatment can modulate hs-CRP concentrations (Rojo-Martinez et al., 2013). Also, to 
enable a more clear understanding from higher results, it was suggested that future studies 
should integrate a full blood count which would enable a more in-depth analysis of cause and 
establish whether acute infection or other sources were responsible for any abnormal readings.  
In relation to the estimation of kidney function, accurate assessment is feasible through the 
measurement of inulin and iohexol clearance (Brandstrom et al., 1998). However these methods 
are not widely available, are costly, and may place a burden on potential or actual participants 
(Botev et al., 2011). Alternatively, in this study the MDRD equation with IDMS-traceable 
creatinine results was chosen as it is commonly used in routine clinical practice. Although, it 
must be said that serum creatinine poses several limitations, this includes the effects of muscle 
mass on reported renal function due to the production of creatinine as a result of muscle 
metabolism (Ikizler and Himmelfarb, 2006). Additionally, serum creatinine is commonly affected 
by dietary factors such as increased meat consumption prior to testing which may have 
influenced the results obtained (Nair, et al., 2014). In previous reports, participants have been 
asked to refrain from eating meat 24 hours prior to testing (Mcintyre et al., 2011). However, in 
this study it was discussed that this would place an increased burden on participants and 
therefore reflect results that were not generalisable to routine clinical practice (Martin et al., 
2005). 
The lack of cystatin C data is also a limitation of this study as recently, experts have proposed 
cystatin C as an alternative to creatinine (O’Riordan et al., 2002). Moreover, this marker of GFR 
offers less dependency on ethnicity, sex, age, and muscle mass or protein intake when compared 
to creatinine and has been found to be an independent predictor of cardiovascular and overall 
mortality. However, when compared to GFR measurement based on the renal clearance of 
exogenous markers, studies have shown that eGFR is more precise when derived from both 
cystatin C and creatinine levels in serum (Stevens et al., 2008). Furthermore, scientists have 
identified cystatin C as being costly and needing further validation across a broad spectrum of 
populations with or without CKD before it can be regarded as a potentially alternative CKD 
marker (Hoek et al., 2003).  
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Study Population  
Overall, target population size was met. However, the ethnic diversities within the group was 
not wide-spread and therefore lacked in this area. As this study involved a random recruitment 
process and dependent on the origin of the study (Lincolnshire) where the non-white population 
make up only 2.4% of the total population, it was non-surprising that we achieved this outcome 
(Lincolnshire Research Observatory, 2011). Nonetheless, it is well known that ethnicity has an 
influence on renal function and would have been an interesting factor to study further, if given 
a higher variability.   
In addition, one limitation that was faced in this study involved the difficulties in recruiting older 
individuals. It is a well-established fact that age-related declines in kidney function are common 
across populations (Weinstein and Anderson, 2010). However, observations from the current 
thesis did not highlight such findings. Had we recruited a more feasible population size for this 
group, this may have changed the outcome of the study and reflect the supported literature on 
this common risk relationship.  
Lastly, one factor that remained unexplored in our study population was the influence of 
socioeconomic status (SES). Past studies have regarded low SES as an associated risk factor for 
reduced renal function (Bello et al., 2008). However, it must be regarded that SES on its own 
does not affect kidney function or share a direct link with CKD onset, but instead the related 
biological exposures (demographic, clinical, behavioural, and healthcare delivery systems) 
would contribute towards the relationship between CKD.  
4.3.3 Implications for Future Research 
Reflecting upon the present thesis, it is evident that introducing a screening programme for 
renal disease for the whole UK population is both unrealistic and likely to be counterproductive. 
Nonetheless, it may be possible to influence a change in the clinical setting with regards to 
general practioners. By opportunistically checking for renal biomarkers (particularly eGFR and 
ACR) in high risk populations, this will allow for the identification of CKD and provide early 
treatment measures for patients which can control for underlying causes such as hypertension 
and diabetes (Yuste et al., 2013).  
As previously discussed, there is a highly associated relationship between renal dysfunction and 
several high-risk diseases (e.g. obesity, hypercholesterolaemia, hypertension, diabetes), as well 
as lifestyle habits (e.g. alcohol consumption or smoking). Thus, the simplest and most effective 
method to limit an increase in CKD prevalence is the prevention of its risk factors. In a healthy 
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population, this may include the awareness of associated risk factors and knowledge on leading 
a healthier lifestyle (e.g. adequate dietary information and regular physical exercise). In those 
with pre-existing comorbidities, this may also include the addition of medical treatments such 
as ACE inhibitors or angiotensin II receptor blockers for chronic hypertension (Kronenberg, 
2009). 
Due the asymptomatic nature of early progressing renal dysfunction, CKD awareness amongst 
patients remains staggeringly low (Plantinga et al., 2010). Timely recognition of CKD could slow 
disease progression, prevent complications, and reduce cardiovascular-related outcomes. 
Additionally, referral to a nephrologist in the early stages of disease has also shown to improve 
outcomes for those who progress to ESRD (Plantinga et al., 2010). It is therefore critical that 
efforts are perused in guiding the implementation of awareness campaigns as well as ensuring 
adequate training in CKD awareness amongst primary care providers (PCP).  
Should funding become available in the future, it would be of great interest to explore the nature 
of risk marker relationships and chronic kidney disease through longitudinal attempts. More 
specifically, the identification of several emerging risk markers such as those associated with 
oxidative stress (advanced oxidation protein products and circulating osteoglycin), inflammation 
(Interleukin-1 receptor 1 and interleukin-6), and immunohistochemical biomarkers (serum 
microfibrillar-associated protein-4 and cholesterol-carrying proteins) (Kronenberg, 2009). Using 
both traditional and novel risk markers of kidney disease, it would be possible to incorporate 
these parameters into various risk prediction models and determine whether their addition 
increases the model’s predictive ability. Overall, this would give a more authentic and reliable 
estimation of CKD and allow for early diagnosis of disease (Upadhyay, 2015).   
Lastly, the growing concerns surrounding the worldwide epidemic of end stage renal disease as 
well as the burden of CKD is one that must be studied further. Such concerns are linked to the 
increasing strain on healthcare costs and the various forms of adverse outcomes from CKD such 
as increased cardiovascular complications and premature mortality (Fraser et al., 2015). Recent 
investigations show that such negative health outcomes can be prevented or at least delayed 
through early detection and prevention programmes (Bastos and Kirsztajn, 2011). In order to 
gain a greater understanding of early disease onset, it is imperative that individuals acquire a 
greater understanding of the burden and risk factors/markers that are associated with CKD in 
the community (Bello et al., 2008).  
If given a repeat opportunity of carrying out the present study, the following suggestions would 
be advised: 
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 Increased sample recruitment of participants and to also include a more even 
distribution of genders and ethnicity. 
 Review of the current protocol to include morning fasting sessions.  
 Further biochemical analysis to include HDL and LDL cholesterol readings as well as full 
blood count and blood ferritin measurements. 
 Revision of literature review on present and future implications within the CKD research 
community.  
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In summary, the findings from this study in combination with previous reports suggest that 
traditional biochemical risk markers such as those for diabetes and obesity may share an 
increased relationship with a reduced kidney function. While we did not see a direct correlation 
between the non-traditional marker, hsCRP, it was possible that this was a consequence of 
insufficient population numbers. 
Overall, this study established that an eGFR of less than 90ml/min/1.73m2 was prevalent in 21% 
of the study population and that increased levels of glucose, fructosamine, triglycerides and 
cholesterol are components of chronic kidney disease which are independent risk factors for the 
development of a reduced kidney function. These findings warrant the need for future clinical 
evaluation to identify whether the effect of preventing and/or treating such risk factors 
predisposing individuals to a reduced kidney function will result in an improved renal prognosis 
and markedly ease the burden of kidney dysfunction in the identified population.  
In addition, investigation of renal equations provided evidence of a greater accuracy in the 
measurement of estimated kidney function using the newer equation system, CKD-EPI, in 
comparison to clinically regarded formulas such as Cockcroft-Gault and MDRD. Furthermore, it 
was highlighted that through the use of the renal equations, correction for both age, gender and 
ethnicity was prominent in this study population, further ensuring the accuracy and reliability of 
these data sets. 
Whereas the sensitivity and the accuracy of the CG formula cannot be overlooked due to the 
influence of weight, CKD-EPI and the MDRD equations are also difficult to calculate in clinical 
practice especially in our setting. However, when CKD-EPI is used bias is enhanced particularly 
at elevated eGFR’s even though precision is not the best. Further studies are therefore, 
warranted prior to the generalization of these findings for patients presenting with chronic 
kidney disease. One theory suggests that increasing age directly affects creatinine production 
on the basis of a reduced overall muscle mass when compared to a younger population. This 
evidence was reflected in this study which highlighted a greater reduction in creatinine with 
increased age in our study population.  
In the present thesis, we also investigated the differences amongst genders which revealed a 
large variance between waist: hip ratio, body fat %, systolic blood pressure and triglyceride 
levels. Differences in morphological characteristics of the two groups seemed to explain the 
reasons behind these variances. Additionally, due to the ease of interpretation of these factors, 
together they may prove beneficial in the assessment of risk of kidney dysfunction and related 
factors in men and women. 
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When evaluated on an additive scale, the modification of these variables by the presence of 
other risk factors has important clinical and public health implications with respect to CKD case 
findings and mass screening strategies. For example, in men with reduced renal function along 
with increased body fat percentage and hypertension, the probability of having CKD and/or 
related disease is much higher. Thus increasing the power of simple clinical measurements to 
identify women and men at high risk of these diseases.  
Previous studies have highlighted the possibility to predict young-onset type 2 diabetes and CVD 
using simple and non-invasive measures of obesity. Our findings from this study may prove to 
be informative for prevention strategies targeting the early-life risk factors for T2DM and CVD.  
As a final note, it is important to emphasize that, at present, it is still unclear which and how 
many patients with CKD will progress to ESRD requiring RRT. Therefore it is extremely difficult 
to assess whether more and more accurate controls for CKD in primary care will automatically 
lead to fewer cases of ESRD and RRT. As already mentioned, the probability of disease 
progression depends on various clinical (age, gender, co-morbidities, smoking), environmental 
(exposure to heavy metals, chemicals, nephrotoxic substances), and genetic factors (family 
history of CKD). However, it is reasonable to assume that interventions slowing or stopping 
disease progression by successfully treating the underlying disease are important to avoid ESRD, 
and might have a greater impact if implemented earlier. 
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Appendix A1 – Ethics and safety approval forms 
EA1 
[doc version 09.02] 
 
Ethical Approval Form:  
Library/Desk/Lab/Studio-
based 
Research Projects 
 
 
 
 
 
 
This form must be completed for each piece of research activity whether conducted by academic staff, 
research staff, graduate students r undergraduates. Applications by students must be endorsed by an 
academic member of staff acting as Principal Investigator/supervisor. The completed form must be sent 
to the designated Ethics Committee within the College. 
Please complete all sections.  If a section is not applicable, write N/A.  
1 Name of Applicant 
 
Kyle Mullan 
2  School  
 
Life Sciences 
3  Position in the 
University 
 
Postgraduate Research Masters 
4 Role in relation to 
this research 
 
Student Researcher 
5 Name(s) of 
collaborators/co-
workers 
 and their 
relationship to the 
project 
 (e.g. supervisor, 
assistant etc.) 
 
 
Name, and role in project: 
1.Dr. Adrian Slee (supervisor)  
2.Dr. Ciaren Graham (supervisor) 
3.Dr. Carol Rea (supervisor) 
 
 
6 Brief statement of 
main Research 
Question or Project 
Title 
 
 
Investigating the Prevalence of Chronic Kidney Disease Risk Factors in a Mixed-Aged 
University Population. 
 
Individuals at risk of CKD share many risk factors, most of which would benefit from 
early detection and intervention. Currently, CKD serves as a major public health 
problem in the UK and throughout the world. Figures from the 2010 NHS Kidney Care 
Association show over 1.8 million people aged over 18 are registered with CKD (stages 
3-5). However, research indicates that many more go undiagnosed until the symptoms 
of chronic kidney failure begin to manifest, supporting the idea for earlier diagnostic 
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and intervention methodologies.  
It is currently known that CKD and CVD share two major risk factors – diabetes and 
high blood pressure. Both can cause damage to the blood vessels in the kidney, 
preventing it from properly eliminating fluid from the body. Additionally, complications 
caused by CKD can also make CVD more likely to occur, this includes: 
- Excess calcium or phosphorus in the blood 
- High homocysteine levels 
- Systemic inflammation 
Since even minor loss of kidney function can drastically increase the danger of 
damaging the heart, several cardio-related complications can occur before the CKD is 
even diagnosed. 
  
Aim/Objective: The project proposes to carry out quantitative and qualitative assays to 
investigate the Incidence of chronic kidney disease risk factors in a mixed-age 
university population and establish the risk of development of CVD, CKD and type 2 
diabetes. Body measurements, food diaries and blood and urine samples will be taken 
from the 150 participants recruited in the study. Samples taken from the participants 
will be analysed for a variety of compositions (glucose, cholesterol, triglycerides, 
glycated haemoglobin, creatinine and CRP ). Results will be analysed along with the 
qualitative measurements to look for any significant correlations.  
 
7 Ethical checklist Does the research involve living human participants, or human tissue?   Yes    No  
    If you answered “yes”, submit form EA2 for Ethical Approval. 
 
Does the research involve living animals, or animal tissue?                      Yes    No  
If you answered “yes”, submit form EA3 for Ethical Approval. 
 
Does the research involve confidential data, or data not in the public 
domain?                                                                                                      Yes    No  
 
Does the project potentially put you or your collaborators at physical or 
psychological risk?                                                                                      Yes    No  
 
Could the topic or results of this research be seen as illegal, or attract 
legal action against the University from an outside agency?                       Yes    No  
 
Could the topic or results of this research attract unwelcome media 
attention, or affect the reputation or standing of the University?                 Yes    No  
 
Could the topic, results or conduct of this research be regarded as 
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offensive, immoral or destructive by some reasonable people?                  Yes    No  
 
Does this research need to be undertaken under a relevant professional 
code of conduct?                                                                                          Yes    No  
 
Are there any potential conflicts of interest in conducting this research, 
including financial gain for the researchers, or for individuals or external 
organizations affiliated with the researchers?                                              Yes    No  
 
Are there any factors inhibiting the application of the University’s  
ethical guidelines,  including those on proper treatment of data, 
research design and publication of results?                                                 Yes    No  
 
Does the research require the approval of any external body?                    Yes    No  
 
 
 
If the answer to all questions above is “No”, you  may complete section 8 to certify 
that there are no ethical issues, submit this form to the relevant Ethics Committee, 
and proceed with the research immediately. You accept professional responsibility 
for this decision, and if unsure should instead submit to the Committee. 
If the answer to any of the above questions is “Yes”, complete the rest of the form, 
submit to the relevant Ethics Committee, and await approval before proceeding  
with the research. Answering “Yes” does not necessarily imply that the research is 
problematic, only the Ethics Committee needs to consider the research to ensure 
that it can proceed, and that the research design conforms to best practice. 
                
8 Self certification of 
Ethical Review 
Having reviewed the ethical implications of this research, I certify that there are no issues 
requiring Ethical Approval. I certify that the research will be carried out in compliance with 
the University’s ethical guidelines for library/desk/laboratory/studio-based research, 
with Health and Safety regulations, and with all other relevant University policies and 
procedures. If there are any changes to the research requiring ethical clearance, I 
shall apply for such clearance before continuing with the research. 
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Signed: 
 
 
 
 
Principal Investigator 
 
Note. This section must be endorsed by the member of academic staff responsible for 
the project. In the case of research by students, the supervising member of  
academic staff must sign. The signed form should then be submitted to the relevant 
Ethics Committee within the College, and the research may proceed.  
 
9 Does the research 
comply with the 
 University’s key 
ethical principles 
 for 
library/desk/lab/studio-
based 
 research ? 
 
 
 
Yes       No    
 
 
If “No”, provide an ethical justification for your project and explain why you wish to 
continue with the research in breach of normal ethical principles:- 
 
 
 
 
 
 
 
 
10 If applicable, please 
state the relevant 
professional code(s) 
under which the 
research is being 
conducted and 
confirm compliance 
 
 
 
 
 
 
11  Does this research 
require the 
 approval of an 
external body ? 
 
 
Yes     No  
 
 
If “Yes”, please state which body:- 
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12  Has ethical approval 
already been 
 obtained from that 
body ?  
 
       Yes    -Please append documentary evidence to this form. 
 
 No    
 
If “No”, please state why not:- 
 
 
 
 
 
Please note that any such approvals must be obtained and documented before the 
project begins. 
13 If there are any 
other ethical issues, 
to which the 
attention of the 
approving 
committee should 
be drawn, please 
state them in this 
section, and explain 
how you have taken 
the issues into 
account, so that the 
research should be 
approved. Please 
consult the 
University’s ethical 
guidelines for 
advice. 
 
Please also include 
here, or attach 
separately, a brief 
description of the 
research, to allow 
the approving 
committee to reach 
judgement. 
 
 
Consent to research 
 
All subjects taking part will be older than 18 years of age, and therefore consent will be 
sought directly from the participants. The participants will be recruited from The 
University of Lincoln. As a researcher I will be using language that is understandable to 
research participants in obtaining their appropriate informed consent, and in the 
information leaflet they will receive regarding the project. All informed consent 
received from the subjects would be appropriately documented prior to any research 
being conducted. In addition subjects will be informed on significant factors that may 
be expected to influence their willingness to participate such as risks involved in taking 
blood, which may cause discomfort and also when taking anthropometric 
measurements.  
 
 Right to withdraw 
 
Participants will be informed of their right to withdraw from the research at any time 
without giving a reason. They will also be informed that they are free to choose not to 
answer any individual questions without giving a reason They will also be informed that 
they are free to withdraw from their questionnaire or other assessments at any time, 
in which case all relevant data will be destroyed and not included in the study. As a 
result of with drawing, as a researcher I will take special care to protect the prospective 
participants from adverse consequences of withdrawing from participation.  
Anonymity and Confidentiality 
Anonymity and confidentiality will be maintained throughout the project. Assessment 
results will be destroyed as soon as possible, and any identifying information will be 
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removed.  Issues of confidentiality and anonymity will also be outlined in the consent 
form sent to participants No information identifying the participants will be generated 
and the data will be fully anonymous in the writing up of the study. Only the researcher 
and their supervisor will have access to personal information relating to the study. All 
participating subjects will be given a number that will be used instead of their name. All 
samples taken will be coded with the number, and only myself and the lecturers will 
know the subjects number.  All forms and paperwork that include the names of the 
participants will be locked away, and any information on a computer will be password 
protected.  
Security and Data Protection 
 
Data will be anonymous and stored on a password-protected computer, and data 
collected will only be used for the purposes of this project. Data will not be left 
unattended on computers; Any hard copies of information such as the questionnaires 
and food diaries will be kept confidential and locked away. 
 
The principle of justice  
 
Subjects will be treated fairly; they will be equitably chosen to ensure certain 
individuals will not feel excluded. Risk markers in a perceived normal population will be 
looked at. 
 
Providing subjects with information about the study 
 
As a researcher, I will provide information to the subjects on the nature of the results, 
explaining why the research project is being carried out, and how the results will effect 
the conclusion. If the participants have any questions, they will be answered as well as 
attempting to correct any misconceptions that participants may have. 
 
Protection of participants 
 
Participants will not be exposed to risks greater than or additional to those 
encountered in their normal lifestyles. Subjects will be protected against any physical 
or mental harm during the investigation, as well as being asked about any factors in the 
procedure that may create a risk, such as pre-existing medical conditions, and will be 
advised of any special action that they should take to avoid risk. 
 
Human Tissue Act 
 
This research is not subject to the Human Tissue Act as serum is being used, and it is 
not regarded as relevant material for the purposes of the Human Tissue Act 2004. 
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APPLICANT SIGNATURE 
 
  
I hereby request ethical approval for the research as described above.  
I certify that I have read the University’s ethical guidelines for library/desk/laboratory/studio-based 
research. 
 
              
_____________________________________   ________________ 
Applicant Signature       Date 
 
 
_____________________________________    
PRINT NAME 
 
 
------------------------------------------------------------------------------------------------------------------------------------------
-------------------------- 
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FOR STUDENT APPLICATIONS ONLY – 
Academic Support for Ethics 
Academic support should be sought prior to submitting this form to the designated Ethics Committee 
within the Faculty. 
. 
 
 Undergraduate / Postgraduate 
Taught application 
Academic Member of staff nominated by the 
School (consult your project tutor) 
 
 Postgraduate Research Application Director of Studies 
I support the application for ethical approval 
 
____________________________________  _________________ 
Academic / Director of Studies Signature                Date 
 
_____________________________________ 
PRINT NAME 
 
----------------------------------------------------------------------------------------------------------------------------- -------------
-------------------------- 
FOR COMPLETION BY THE DESIGNATED ETHICS COMMITTEE WITHIN THE COLLEGE 
 
Please select ONE of A, B, C or D below: 
 
  A. Ethical approval to this research. 
 
  B. Conditional ethical approval to this research. 
     
 
10  Please state the condition (inc. 
 date by which condition must be 
 satisfied if applicable) 
 
 
      
 
 
 
 
 
  C. Ethical approval cannot be given to this research but the application is referred on to the 
University Research Ethics Committee for higher level consideration. 
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11  Please state the reason 
 
 
      
 
 
 
 
  D. Ethical approval cannot be given to this research and it is recommended that the research 
should not proceed. 
     
 
12  Please state the reason, bearing 
in mind the University’s ethical 
framework, including the primary 
concern for Academic Freedom. 
 
 
      
 
 
 
 
Signature of the Chair of the designated ethics committee within the College 
 
Signature: 
________________________________________Date:________________________________________
___ 
 
Chair of_______________________________________________ 
Key ethical guidelines for library/desk/laboratory/studio-based research 
 
The University of Lincoln has drawn up the following key principles for researchers engaged in 
library/desk/laboratory/studio-based projects in order to promote high professional standards. They 
should be read alongside the University’s Ethical Principles for Conducting Research with Humans and 
Other Animals, and operate as part of the University’s Ethical Framework. 
 
 Non-falsification of data: Researchers have an ethical obligation to refrain from tampering with data. 
Thus questionnaire responses, experimental observations and data analyses should not be 
fabricated, altered nor discarded. In addition, researchers have a responsibility to exercise reasonable 
care in processing data to ensure no errors affect the results. 
 Ethics of reporting research: Researchers are obliged to give full and proper attribution of ideas: 
presenting the words, data or ideas of another person as your own without properly citing them 
amounts to plagiarism. This is not only misconduct but can also be an infringement of copyright, 
amounting to theft of intellectual property.  
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 Ethics and research design: Researchers should be open to a range of methods: failure to consider 
and evaluate alternative methods and tools for the collection of data may be regarded as too overtly 
biased. All appropriate steps should be taken to ensure that no samples are obtained from unethical 
sources e.g. illegal databases; unregistered suppliers of samples from humans or other animals.  
 Authorship credit: Only those researchers who are significant contributors to a research project 
should be given authorship credit. A “significant contributor” might be described as a person playing 
a major role in conceptualising, analysing or writing the final document. Ideally, all those involved in 
the research project should decide upon the order of authorship. Usually, the first author is the one 
who has made the biggest contribution. 
 Conflict of interest: Researchers should be aware of the potential influence of personal or commercial 
interests on their work and take all practical measures to ensure that information is presented 
without distortion. 
 The principle of beneficence: Researchers are required to protect individuals by seeking to maximise 
anticipated benefits and minimise possible harms. It is therefore necessary to examine carefully the 
design of the study and its risks and benefits including, in some cases, identifying alternative ways of 
obtaining the benefits sought from the research. Research risks must always be justified by the 
expected benefits of research.  
 Professional codes: Researchers should undertake research legally and in accordance with any 
relevant professional codes of conduct.  
 Personal  information: Researchers should anonymise information which relates to individuals 
when they have not obtained informed consent, unless there is a clear justification to the contrary. 
They should also be aware of the impact of wider public dissemination of their work and the impact 
this might have on any individual or group of individuals. If it is anticipated that it might cause distress, 
it is essential to demonstrate that the benefits outweigh this risk. 
 
 
 
  
    
 
9  
Statement of the ethical issues 
involved and how they are to 
be addressed –including a risk 
assessment of the project based 
on the vulnerability of 
participants, the extent to which it 
is likely to be harmful and whether 
there will be significant 
discomfort. 
 
 
(This will normally cover such 
issues  as whether the 
risks/adverse effects 
associated with the project have 
 
Consent to research 
 
All subjects taking part will be older than 18 years of age, and therefore 
consent will be sought directly from the participants. The participants will be 
recruited from The University of Lincoln. As a researcher I will be using 
language that is understandable to research participants in obtaining their 
appropriate informed consent, and in the information leaflet (Participant 
Information Sheet) they will receive regarding the project. All informed 
consent received from the subjects would be appropriately documented prior 
to any research being conducted. In addition subjects will be informed on 
significant factors that may be expected to influence their willingness to 
participate such as risks involved in taking blood, which may cause discomfort 
and also when taking anthropometric measurements.  
 
 Right to withdraw 
 
Participants will be informed of their right to withdraw from the research at 
any time without giving a reason. They will also be informed that they are free 
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been dealt with and whether the 
benefits of research outweigh the 
to choose not to answer any individual questions without giving a reason They 
will also be informed that they are free to withdraw from their questionnaire 
or other assessments at any time, in which case all relevant data will be 
EA2 
 
Ethical Approval Form:  
Human Research Projects 
 
 
Please word-process this form, 
handwritten applications will not be 
accepted 
 
 This form must be completed for each piece of research activity whether conducted by academic staff, 
research staff, graduate students or undergraduates. The completed form must be approved by the 
designated authority within the College. 
Please complete all sections.  If a section is not applicable, write N/A.  
 
1 Name of Applicant 
 
 
 
Kyle Mullan 
 
School: 
Life Sciences 
College: 
College of Science 
 
 
2  Position in the 
University 
 
Post Graduate Research Masters 
 
3 Role in relation to 
this research 
 
Student Researcher  
 
4 Brief statement of  
 main Research 
Question 
 
 
 
Investigating the Prevalence of Chronic Kidney Disease Risk Factors in a Mixed-Aged 
University Population. 
 
 
5 Brief Description of 
Project 
 
 
 
 
Investigating the Prevalence of Traditional and Novel Chronic Kidney Disease Risk 
Factors in a Mixed-Aged University Population. 
 
Individuals at risk of chronic kidney disease (CKD) share many risk factors, most of which 
would benefit from early detection and intervention. Currently, CKD is a major public 
health problem in the UK and throughout the world. Figures from the 2010 NHS Kidney 
Care Association show over 1.8 million people aged over 18 in the UK are registered with 
CKD (stages 3-5). However, research indicates that many more go undiagnosed until the 
symptoms of chronic kidney failure begin to manifest, supporting the idea for earlier 
diagnostic and intervention methodologies.  
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It is currently known that CKD and CVD share two major risk factors – diabetes and high 
blood pressure. Both can cause damage to the blood vessels in the kidney, preventing it 
from properly eliminating fluid from the body. Additionally, complications caused by CKD 
can also make CVD more likely to occur, this includes; excess calcium or phosphorus in 
the blood, anemia, high homocysteine levels, systemic inflammation. 
 
Since even minor loss of kidney function can drastically increase the danger of damaging 
the heart, several cardio-related complications can occur before the CKD is even 
diagnosed. 
  
Aim/Objective: The project proposes to carry out quantitative and qualitative measures 
to investigate the incidence of CKD risk factors in a mixed-age university population and 
establish the risk of development of CVD, CKD and type 2 diabetes. Body measurements 
(height, weight, body fat percentage, waist and hip circumference), haemodynamic 
function (heart rate and blood pressure), food diaries and blood samples will be taken 
from the 150 participants recruited in the study. Samples taken from the participants will 
be analysed for a number of variables (glucose, cholesterol, triglycerides, glycated 
haemoglobin, creatinine and CRP). Results will be analysed along with the qualitative 
measurements to look for any significant correlations and group analyses performed 
using SPSS.  
 
 
 
 
 
 
 
Approximate Start Date:   
November 2014 
 
 
Approximate End Date:    
August 2014 
 
6 Name of Principal 
Investigator 
 or Supervisor 
 
 
Dr. Adrian Slee 
Dr. Ciaren Graham 
Dr. Carol Rea 
 
Email address:  
cgraham@lincoln.ac.uk 
crea@lincoln.ac.uk 
aslee@lincoln.ac.uk  
 
Telephone: 
6897 
6819 
 
Page | 104 
 
risks) 
 
 
destroyed and not included in the study. As a result of with drawing, as a 
researcher I will take special care to protect the prospective participants from 
adverse consequences of withdrawing from participation.  
 
Anonymity and Confidentiality 
 
Anonymity and confidentiality will be maintained throughout the project. 
Assessment results will be destroyed as soon as possible, and any identifying 
information will be removed.  Issues of confidentiality and anonymity will also 
be outlined in the consent form sent to participants No information 
identifying the participants will be generated and the data will be fully 
anonymous in the writing up of the study. Only the researcher and their 
supervisor will have access to personal information relating to the study. All 
participating subjects will be given a number, that will be used instead of their 
name. All samples taken will be coded with the number, and only myself and 
the lecturers will know the subjects number.  All forms and paperwork that 
include the names of the participants will be locked away, and any 
information on a computer will be password protected.  
 
 
Security and Data Protection 
 
Data will be anonymous and stored on a password-protected computer, and 
data collected will only be used for the purposes of this project. Data will not 
be left unattended on computers; Any hard copies of information such as the 
questionnaires and food diaries will be kept confidential.  
 
The principle of justice  
 
Subjects will be treated fairly; they will be equitably chosen to ensure certain 
individuals will not feel excluded. Risk markers in a perceived normal 
population will be looked at. 
 
 
7 Names of other 
researchers or 
 student 
investigators involved 
 
Nikita Gug 
 
 
8 Location(s) at which 
project is to be carried 
out 
 
Joseph Banks Labs (Science Building), and MHT 
Joseph Banks Laboratories Beevor Street, University of Lincoln, Lincoln LN6 7DL 
MC3133 Dry Lab 
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Providing subjects with information about the study 
 
As a researcher, I will provide information to the subjects on the nature of the 
results, explaining why the research project is being carried out, and how the 
results will effect the conclusion. If the participants have any questions, they 
will be answered as well as attempting to correct any misconceptions that 
participants may have. 
 
Protection of participants 
 
Participants will not be exposed to risks greater than or additional to those 
encountered in their normal lifestyles. Subjects will be protected against any 
physical or mental harm during the investigation, as well as being asked about 
any factors in the procedure that may create a risk, such as pre-existing 
medical conditions, and will be advised of any special action that they should 
take to avoid risk. 
 
Human Tissue Act 
 
This research is not subject to the Human Tissue Act as serum is being used, 
and it is not regarded as relevant material for the purposes of the Human 
Tissue Act 2004.  
 
 
 
Ethical Approval From Other Bodies 
 
 
10  Does this research require 
the approval of an external 
body ? 
 
 
Yes     No  
 
 
If “Yes”, please state which body:- 
 
 
 
X 
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11  Has ethical approval already 
been obtained from that body ?  
 
       Yes    -Please append documentary evidence to this form. 
 
 No    
 
If “No”, please state why not:- 
 
 
 
 
 
Please note that any such approvals must be obtained and documented before 
the project begins. 
 
 
APPLICANT SIGNATURE 
 
I hereby request ethical approval for the research as described above.  
I certify that I have read the University’s ETHICAL PRINCIPLES FOR CONDUCTING RESEARCH WITH 
HUMANS AND OTHER ANIMALS. 
 
         
_____________________________________   ________________ 
Applicant Signature       Date 
 
 
_____________________________________    
PRINT NAME 
 
 
----------------------------------------------------------------------------------------------------------------------------- -------------
-------------------------- 
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FOR STUDENT APPLICATIONS ONLY – 
Academic Support for Ethics 
 
Academic support should be sought prior to submitting this form to the designated Ethics Committee 
within the Faculty 
. 
 
 Undergraduate / Postgraduate Taught application A        Academic Member of staff nominated by the 
School (consult your project tutor) 
 
 Postgraduate Research  
 Application 
                Director of Studies 
 
I support the application for ethical approval 
 
 
 
_____________________________________   _________________ 
Academic / Director of Studies Signature                Date 
 
 
_____________________________________ 
PRINT NAME 
 
 
----------------------------------------------------------------------------------------------------------------------------- ----------------------------
------------ 
 
 
FOR COMPLETION BY THE DESIGNATED ETHICS COMMITTEE WITHIN THE COLLEGE 
 
Please select ONE of A, B, C or D below: 
 
  A. Ethical approval is given to this research. 
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  B. Conditional ethical approval is given to this research. 
     
 
10  Please state the condition (inc. 
 date by which condition must be 
 satisfied if applicable) 
 
 
      
 
 
 
 
 
 
  C. Ethical approval cannot be given to this research but the application is referred on to the 
University Research Ethics Committee for higher level consideration. 
     
 
11  Please state the reason 
 
 
      
 
 
 
 
 
 
  D. Ethical approval cannot be given  to this research and it is recommended that the research 
should not proceed. 
     
 
12  Please state the reason, bearing 
in mind the University’s ethical framework, 
including the primary concern for Academic 
Freedom. 
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Signature of the Chair of the designated Ethics Committee within the College 
 
    
   
    
_____________________________________   ________________ 
Signature       Date 
 
Chair of_______________________________________________ 
 
 
 
Science Building 
School of Life Sciences 
 
COSHH ASSESSMENT FORM  
 
Name 
 
Nikita Gug & Kyle Mullan 
Name of Supervisor Ciaren Graham 
Carol Rea 
Adrian Slee 
Title of Project 
 
Horiba BioAnalyser 
Procedure Measurement of Cholesterol, Glucose and 
Trigylcerides 
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BRIEF DESCRIPTION OF PROCEDURE 
Measurement of Glucose: Enzymatic method (hexokinase) Hexokinase catalyses the 
phosphorylation of glucose in the sample by ATP producing ADP and glucose-6-phosphate. 
Glucose-6-phosphate is oxidised to 6-phosphogluconate with the reduction of NAD+ to NADH 
by G-6-PDH. The amount of NADH formed is proportional to the concentration of glucose in 
the sample and can be measured by the increase in absorbance at 340 nm. 
 
Measurement of Cholestrol. ‘’CHOD-PAP’’: enzymatic photometric test. Determination of 
cholesterol after enzymatic hydrolysis and oxidation. The colorimetric indicator is 
quinoneimine which is generated from 4-aminoantipyrine and phenol by hydrogen peroxide 
under the catalytic action of peroxidase (Trinder’s reaction). 
 
Measurement of triglycerides. A series of enzymatic reactions, again as in the test for 
cholesterol, quinoneimine is produced which is measured photometrically  
 
Measurement of glycated haemoglobin (HbA1c). Whole blood samples are pre-treated with 
the Haemolysis Reagent to lyse the red cells and hydrolyze the haemoglobin chain. Total 
Haemoglobin is converted into alkaline haematin in the alkaline solution of a non-ionic 
detergent. HbA1c is measured from the hemolysate by a latex enhanced turbidimetric 
immunoassay. 
 
Measurement of high-sensitivity C-reactive protein (Hs-CRP). When an antigen-antibody reaction occurs 
between CRP in a sample and anti-CRP antibody which has been sensitized to latex particles, 
agglutination results. This agglutination is detected as an absorbance change, with the magnitude of the 
change being proportional to the quantity of CRP in the sample. The actual concentration is then 
determined by interpolation from a calibration curve prepared from calibrators of known concentration.   
 
Measurement of Creatinine. An in vitro diagnostic assay for the quantitative in vitro 
determination of creatinine in human serum, plasma and urine based on an enzymatic 
method using a multi-step approach ending with a photometric end-point reaction. It is 
composed of a bi-reagent cassette (R1= 22 mL;R2= 8 mL).   
 
All reagents come supplied ready for use; the cap of the reagent cassette is removed and 
placed in the refrigerated ABX Pentra 400 reagent compartment.  
TABLE 1.  CHEMICALS USED 
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Chemical name and 
concentration (including 
constituents of mixtures) 
Or micro-organism, dust etc 
Maximum 
quantity 
present 
Hazard 
category 
(Or micro-
organism 
category) 
Physical form 
(Gas, liquid, 
solid) 
Hazard 
rating 
(Low, 
Medium, 
High, 
Extreme) 
1 Pentra Glucose HK CP is 
ready-to-use.   
Composition.  
Reagent 1 Pipes Buffer, 
pH 7.60 100 mmol/l NAD 
3.8 mmol/l 
ATP 2.2 mmol/l Sodium 
azide < 0.1 %  
 
Reagent 2: Hexokinase 
8500 U/l G-6-PDH 8500 
U/l Magnesium sulphate 
20 mmol/l Sodium azide 
< 0.1 % 
 
 
 
Reagent 1 : 56 
ml 
Reagent 2 : 14 
ml 
Toxic.  Irritant Liquid Medium 
2 ABX Pentra Cholesterol 
CP is ready-to-use.  
Composition.  
Good’s buffer pH 6.7 50 
mmol/l, Phenol 5 mmol/l 
4-Aminoantipyrine 0.3 
mmol/l, Cholesterol 
esterase (CHE)  200 U/l, 
Cholesterol oxidase 
(CHO) 50 U/l, Peroxidase 
(POD) 3 kU/l 
Sodium azide 0.95 g/l 
 
 
90 ml 
 
Toxic.  Irritant Liquid Medium 
Page | 112 
 
3 ABX Pentra Triglycerides 
CP is ready-to-use. 
Composition.  
Pipes free acid 50 mmol/l 
Sodium hydroxide 3.36 
g/l 
Triton X-100 1 ml/l 
Magnesium salt 14.8 
mmol/l 
p-chlorophenol 2.69 
mmol/l 
ATP 3.14 mmol/l Sodium 
azide 7.99 mmol/l, 
Potassium ferrocyanide 
9.94 mol/l, 4-
aminoantipyrine 0.31 
mmol/l Lipoprotein 
lipase 1.90 U/l 
Glycerokinase 0.5050 
KU/l 
Glycerol phosphate 
Oxidase 4.15 KU/l 
Peroxidase 0.4950 KU/l 
Distilled water qs 1l/l 
 
90 ml Toxic.  Irritant Liquid Medium 
 ABX Pentra HbA1c WB 90ml Toxic. Irritant Liquid Medium 
 ABX Pentra Creatinine 
CP 
90ml Toxic. Irritant Liquid Medium  
 ABX Pentra High 
Sensitive C-Reactive 
Protein 
90ml Toxic. Irritant Liquid Medium 
Ex = Explosive, To = Toxic, Co = Corrosive, Ha = Harmful, Ir = Irritant, Fl = Flammable, HF = 
Highly Flammable, Ox = Oxidising, Ca = Carcinogenic, Ter = Teratogen,  Mu = Mutagen 
 
SPECIFIC DETAILS FOR HIGH RISK CHEMICALS 
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TABLE 2.  EXPOSURE POTENTIAL 
Che
m no.  
Exposure 
Potential  
Possible Route of Entry 
 (tick)  
Frequency 
of Use  
Length of 
exposure 
 (Low, Med, High) Skin Eyes Inhal. Ingest.   
1 Low x x x x Once <10mins 
2 Low x x x x Once <10mins 
3 Low x x x x Once <10mins 
4 Low x x x x Once <10mins 
5 Low x x x X Once <10mins 
6 Low x x x x Once <10mins 
7        
8        
9        
10        
 
 
 
Containment Level for Procedure: 
 
1 
 
Containment 
Level 
Control Measures 
1 Laboratory coat must always be worn, safety spectacles and gloves are 
recommended.  Work may be carried out on the bench 
2 Laboratory coat and gloves must be worn. Work should be carried out in a 
properly tissue culture hood. 
3 Laboratory coat, safety spectacles and gloves must be worn. Work should 
be carried out in a properly functioning fume cupboard. Additional safety 
measures may be required. Full details to be entered below. 
 
 
PERSONAL PROTECTIVE EQUIPMENT AND ENGINEERING CONTROLS TO BE USED DURING 
PROCESS 
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Laboratory coat must always be worn, safety spectacles and gloves are recommended.  Work 
may be carried out on the bench  
 
(Protective clothing, gloves (state material), eye/face protection, dust mask, respirators, fume 
cupboard, class II cabinet etc.) 
 
FIRST AID 
Eyes: Check for and remove contact lenses and flush with copious amounts of water; 
assure adequate flushing by separating the eyelids with fingers; call a physician 
Skin: Generally the product does not irritate the skin. However flush with copious 
amounts of water; remove contaminated clothing and shoes; call a physician 
Inhalation: Supply fresh air; consult doctor in case of complaints 
Ingestion: If swallowed, wash out mouth with copious amounts of water; call a physician  
 
 
WASTE DISPOSAL  
 
Solvents used are divided into chlorinated and unchlorinated waste and are 
placed in solvent waste bottles ready for safe disposal. Oils and fats are disposed 
of carefully in waste bottles. It is important they are NOT disposed of down the 
sink.  
Some chemicals can go down the sink if they are diluted with plenty of running 
water. 
Important to always check the method of disposal on the material safety data 
sheet (MSDS) or seek advice from technical staff. 
 
 
 
Assessor(s) 
 
Nikita Gug & Kyle Mullan 
Date: 22/10/2014 
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Checked and approved by 
 
 
Date:  
 
 
 
Appendix A2 –Participant information form 
 
 
Participant Information Form 
Participant Number ___________ 
 
To investigate the potential risk factors associated with the 
development of cardiovascular disease and metabolic diseases such 
as type 2 diabetes. This will be performed in a mixed university 
population (i.e. students and staff). 
 
Introductory outline  
 This study is part of MRes research studies for Nikita Gug and Kyle 
Mullan, Postgraduate Researchers, Biomedical Science, School of 
Life Sciences. This study is being supervised by Dr. Adrian Slee, Dr. 
Ciaren Graham and Dr. Carol Rea.  
What is the purpose of this study? 
 To investigate the potential risk factors associated with the development 
of cardiovascular disease (CVD), metabolic diseases such as type 2 
diabetes mellitus (T2DM) and related metabolic syndrome (MetS) and 
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chronic kidney disease (CKD). This will be performed in a mixed university 
population (i.e. students and staff).   
Am I suitable for this study (Inclusion, exclusion criteria) 
 To participate in this study, the participants need to be over the age of 18 
years and be able to provide written consent. If they are pregnant, 
unfortunately they cannot take part in this study. Additionally, if they have 
been previously diagnosed with diabetes, cardiovascular problems or 
kidney disease they cannot take part. If they have a clinically diagnosed 
disorder, they should consult the principal investigators and find out 
whether they can take part in this study. If the participants have a fitted 
electrical device you will not be able to take part in the study. If you would 
like to take part, we would like you to complete a five day food diary and a 
general questionnaire. We would also like to take some non-invasive body 
composition measurements including height, weight, body mass index, 
body circumferences (waist, hip) and percentage body fat using a bio-
electrical impedance device. Blood pressure and heart rate will also be 
taken in the rested state. Finally, we would like to take a small sample (2 
x 4ml) of blood from your arm. Please note that a bio-electrical 
impedance for measuring fat mass will be used, therefore if you have 
any electrical device fitted such as a cardiac pacemaker, 
unfortunately we will not be able to include you in this study.  
Days of Research 
 Week 11 – Wednesday 3rd December 2014 
 Week 12 - Monday 8th December and Tuesday 9th December 2014 
Location: MHT Building, Dry Lab MC3133 and Science Building, 
SB012 
Participants will only be required to attend once and a time and date will be 
allocated. 
Do I have to take part? 
 No. You can withdraw from the study at any time without a reason. You 
will also be informed that you are free to choose not to answer any 
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individual questions without giving a reason, and you are free to withdraw 
from the questionnaire or other assessments at any time, in which case all 
relevant data will be destroyed and not included in the study. If you have 
any questions, please do not hesitate in contacting the principal 
investigators using the details at the bottom of this page. Please note 
ethical approval has been permitted to allow this study to take place and 
has been passed through the school of life sciences. 
 
 
Are there any risks/hazards I should be aware of before taking part? 
 All tests are safe and non-invasive. There is minimal risk and harm for 
participants. With regards to blood phlebotomy, blood will be taken by a 
trained phlebotomist. The health and safety of each participant is of great 
importance, and at no point will it be compromised. The bioelectrical 
impendence should not be performed on any individual with a 
pacemaker, fitted electrical medical device or pregnant.   
Summary of additional forms prior to the research  
- Participant Information Sheet 
- Consent form 
- Questionnaire 
Summary of measurements being taken 
- Height 
- Weight 
- Body Mass Index  
- Waist Circumference  
- Hip Circumference  
- Bioelectrical impedance assessment (assessment of body composition 
and fat mass) 
- Resting blood pressure and heart rate 
- Blood measures including; cholesterol, blood glucose (including 
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glycated haemoglobin HbA1c), triglyceride, creatinine, C-reactive 
protein, serum ferritin, serum Iron. 
 
The diet diary  
 A five day diet diary needs to be completed, and should include a log of 
everything you consume. This study requires the food diary to be started 
on a Thursday, and finished on a Monday at 23.59pm. 
  Participants should use a paper diary to record and track everything 
consumed. Your researcher will give you a paper diary. 
 This study relies on your honesty when logging your diet diary. Please do 
not feel under any pressure to change what you eat because you are filling 
out the diary. 
What will happen with my results? 
 All participant information and data will be completely confidential and 
participants anonymised and given a unique code. All forms and 
paperwork will be kept safe within a lockable cabinet within a lockable 
room at the university. All electronic data will be kept on password 
encrypted computer. Only the principal investigators and supervisors will 
have access to participant information. Specific data from participants 
such as questionnaire and diet diary information will be analysed 
alongside other participants, correlations and significant relationships will 
be established and aim to publish results.  
 
Your participation is appreciated and please feel free to contact us further. 
 
Contact Information  
Principal investigators – Nikita Gug & Kyle Mullan 
Email – ngug@lincoln.ac.uk & kmullan@lincoln.ac.uk   
Supervisors: 
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Dr. Adrian Slee – aslee@lincoln.ac.uk 
Dr. Ciaren Graham- cgraham@lincoln.ac.uk 
Dr. Carol Rea- crea@lincoln.ac.uk  
 
Appendix A3–Participant consent form 
 
Participant Consent Form 
 
Participant Number ___________ 
 
An Investigation into the Prevalence of Traditional and Non-
Traditional Risk Factors for Cardiovascular and Related 
Metabolic Diseases 
 
Thank you for showing interest in the study. Please ensure that you have read 
through and understand all the information given to you in the participant 
information pack. If you have any questions, please do not hesitate to contact 
the researcher before signing this form. Your participation is greatly appreciated 
by the primary researcher and all the other participants and researchers 
involved. 
Please tick the appropriate box for each statement below: 
 I confirm that I have read and fully understood the information on the 
research information sheet. I have had the chance to ask questions 
and have received satisfactory answers. 
Agree □ Disagree □ 
 
 I am aware that a bioelectrical impendence is used in the research and 
it involves the submission of a small electric current through the body. 
I can also confirm that I do not have any electrical medical devices on 
my person (e.g. cardiac pacemaker). 
Agree □ Disagree □ 
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 I understand that researchers may use data collected during the study, 
I give permission for these individuals to have access to my data, and 
understand the results from the study could go towards a student 
publication; however your identity will be kept anonymous. Only the 
researchers and supervisors will have access to personal information 
relating to the study. 
Agree □ Disagree □ 
 
 I am aware that 8ml of blood will be taken from my arm using a syringe 
and needle, and blood will be tested for typical risk markers for 
cardiovascular disease, type 2 diabetes and chronic kidney disease 
(e.g. blood glucose, triglyceride, cholesterol and creatinine levels).  
Agree □ Disagree □ 
 
 I am aware that weight, height, hip and waist circumference, skin fold 
thickness, body composition, body fat percentage and blood pressure 
measurements will be taken. 
Agree □ Disagree □ 
 
 I agree to complete a five day food diary. 
Agree □ Disagree □ 
 
 I am aware that all data will be kept confidential and stored in a secure 
and safe manner. 
Agree □ Disagree □ 
 
 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason.  
Agree □ Disagree □ 
 
If you have selected ‘Disagree’ to any of the statements above, you may not be 
eligible to participate in this study and you should speak to the primary 
researcher. 
By signing this form you are aware of what the study entitles and you confirm that 
all questions on this form have been honestly answered.  
 
Participant name …………………………………………………… 
Participant signature ………………………………………………             
Date ………………………… 
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Primary researcher name ……………………………………… 
Primary researcher signature ………………………………..              
Date …………………………. 
 
 
 
Appendix A4–Participant information booklet
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Appendix A5–Participant lifestyle questionnaire  
 
 
Questionnaire 
Participant Number ___________ 
 
An Investigation into the Prevalence of Traditional and Non-
Traditional Risk Factors for Cardiovascular and Related Metabolic 
Diseases 
 
Personal Information 
 
1. Age ________ 
 
2. What is your occupation? 
 
Student  
Lecturer  
Other (please state) 
____________________________ 
 
3. Contact telephone 
number:_____________ 
 
4. Contact 
email:_________________________ 
      
5. Sex: 
 
Male  
Female  
Other (please state) ___________ 
 
6. Ethnicity?  
     
White  
Black  
Asian  
 
Medical History 
 
7. Do you currently suffer from any 
medical conditions? 
 
No  
Yes  
If yes, please state below: 
                                       
 
8. Do you regularly take any prescription 
medication?  
 
No  
Yes  
If yes, please state below: 
                       _____________ 
 
9. Have you had any surgery in the past 
year? 
 
No  
Yes  
If yes, what was the surgery for? 
_________________________________
_ 
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Other (please state): ___________ 
           
 
 
 
Medical History Continued 
 
 
11. Do you have any of the following?   
(if known) 
 
 Chest pain during resting 
activity  
No  Yes   
 Chest pain during physical 
activity 
No  Yes  
 Light headedness  
No  Yes  
 Unusual shortness of breath  
No  Yes  
 Cramping pains in legs or feet  
No  Yes  
 
12. Do you or any of your immediate 
family have any of the following 
conditions: 
 
 Heart problems  
Self  Immediate Family  
 Diabetes (Type 1) 
Self  Immediate Family  
 Diabetes (Type 2) 
Self  Immediate Family  
 Chronic Kidney Disease 
Self  Immediate Family  
 Stroke  
Self  Immediate Family  
 Anaemia  
10. Are you pregnant now, or have you 
given birth in the past 6 months? 
 
   Yes  
No  
 
 
 
Lifestyle 
 
13. Have you ever received a flu 
vaccination? 
 
   Yes  
   No  
 
14, If you answered ‘Yes’ to question 13, 
when? 
 
 
15. How many cigarettes do you smoke 
per day? 
 
I do not smoke  
Less than 10  
10-20  
20-30  
>30  
If other, please state (Includes nicotine 
patches, pipes, cigars and e-cigs): 
_________________________________ 
 
16. If you answered ‘I do not smoke’ to 
question 15, have you ever smoked? 
 
No  
Yes   
If yes, how long ago and approximately 
how many? 
_________________________________
      
17. How many units of alcohol do you 
consume in an average week? Please use 
the table as a unit reference: 
 
 
Alcoholic beverage Number of 
units 
Small glass of wine (175ml) 1.5 
Large glass of wine (250ml) 3 
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Self  Immediate Family  
 High Blood Pressure  
Self  Immediate Family  
 
 
 
Lifestyle continued 
 
18. Please list your average daily 
activities at home including the 
duration (e.g. housework, gardening, 
caring for children): 
 
Activities Time (mins) 
  
  
  
  
  
  
  
 
19. Please list your average daily 
activities at work (e.g. manual 
handling, desk work, lecturing, 
attending lectures): 
 
Activities Time (mins) 
  
  
  
  
  
  
  
 
                             ______ Units 
 
 
 
 
 
20. How do you travel to university/work? 
(More than one can apply): 
 
Walk  
Car  
Cycle  
Train  
Bus  
Other (please state) _________________ 
 
21. How many times a week do you take 
part in structured physical activities for 
more than 30 minutes at a time? 
 
0  
1-2  
3-4   
5-6  
More than 6  
 
22. When you take part in structured 
physical activity, how intense is your 
workout? 
 
E.g: 
 Light (not really sweating) 
 Moderate (out of breath and slightly 
sweating) 
 Intense (out of breath and not able 
to hold a conversation). 
 
I do not take part in physical activity  
Light  
Moderate  
Intense   
 
23. Would you like to be more 
active/exercise more frequently? 
 
   Yes  
   No  
Pint of beer/lager/cider 
(568ml) 
3 
Single shot of spirit (35ml) 1 
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Lifestyle continued 2 
 
24. If yes, why do you not? 
 
   Not enough money  
   Not enough time  
   No energy  
   Other (please 
state)________________ 
 
 
25. How deep a sleeper are you? 
 
   Light Sleeper (e.g. easily woken up by                
   noises, struggle to fall asleep)  
   Medium Sleeper (Sometimes woken 
by     
   noises but not often, fall asleep 
relatively     
   easily)  
   Heavy Sleeper (Rarely woken up by  
   noises, fall asleep easily)  
 
 
26. On average what time do you go 
to sleep? 
   Before 9pm  
   9-11pm  
   11pm-1am  
   1-3am  
   After 3am  
 
27. How many hours of sleep do you 
have on average per night? 
 
More than 8 hours  
6-8 hours  
4-6 hours  
Less than 4 hours  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28. If stress is defined as feeling irritable, 
anxious, or having sleeping difficulties, 
how often have you felt stress as a result 
of conditions at home or at work? 
 
   Never experienced stress   
   Experience some periods  
   at home or at work  
   Experience several periods  
   at home or at work  
   Experience permanent stress  
   at home or at work  
 
 
29. In your immediate family, what is the 
highest level of education achieved? 
 
   None  
   Don’t Know  
   GCSE/O levels (or equivalent)  
   A Levels  
   Degree  
   Postgraduate Degree  
   Other (please state) _________________ 
 
Diet 
 
30. Are you on any special diet? 
 
No  
Vegetarian  
Vegan  
Gluten Free  
Dairy Free  
   Other _________________ 
 
 
31. Would you consider yourself to have a 
healthy diet? 
 
Yes  
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32. Do you normally eat breakfast in 
the morning? 
 
Yes  
No  
 
33. Do you snack in-between 
meals?      
 
Yes  
No  
 
34. Do you think you eat more than 
you need to or eat past the point of 
fullness? 
 
Yes  
No  
 
 
 
 
 
 
      
No  
 
 
 
 
 
 
 
 
35. How often do you eat a takeaway? 
 
More than once a week  
Once a week  
Once a month  
Once every few months  
Never  
 
36. Do you skip meals? 
 
Yes  
   No  
 
37. How often do you eat vegetables, 
fruit? 
 
Everyday  
Not everyday  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for completing this questionnaire. 
Please hand it back to the principal investigator (Kyle), and if you have 
any questions, feel free to contact us. 
 
